Scorpius (SCPX) S-1 21 Jan 16 IPO registration Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Sep. 30, 2015
Document and Entity Information [Abstract]
Document Type	S1
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Entity Registrant Name	HEAT BIOLOGICS, INC.
Entity Central Index Key	1,476,963
Entity Filer Category	Smaller Reporting Company

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Current Assets
Cash and cash equivalents	$ 8,210,938	$ 3,714,304	$ 4,566,992
Investments, held to maturity (net)	6,742,987	10,698,982	17,297,165
Prepaid expenses and other current assets	986,264	863,227	1,066,638
Total Current Assets	15,940,189	15,276,513	22,930,795
Property and Equipment, net	467,999	445,534	53,753
Other Assets
Restricted cash	101,146	101,129	1,252
Deposits	69,798	19,798	9,320
Related party receivable	58,017	48,642	$ 24,946
Deferred financing costs, net	25,379	24,554
Total Other Assets	254,340	194,123	$ 35,518
Total Assets	16,662,528	15,916,170	23,020,066
Current Liabilities
Accounts payable	936,361	1,367,426	651,917
Accrued expenses and other payables	2,074,174	$ 805,968	503,050
Accrued interest			$ 25,364
Current portion of long term debt	2,053,859	$ 397,465
Total Current Liabilities	5,064,394	2,570,859	$ 1,180,331
Long Term Liabilities
Long term debt, net of discount and current portion	2,831,787	$ 2,314,124
Other long term liabilities	12,228		$ 122,590
Total Liabilities	$ 7,908,409	$ 4,884,983	$ 1,302,921
Commitments and Contingencies
Stockholders' Equity
Common stock, $.0002 par value; 50,000,000 shares authorized, 8,415,434 and 6,492,622 shares issued and outstanding at September 30, 2015 (unaudited) and December 31, 2014, respectively	$ 1,365	$ 982	$ 961
Additional paid in capital	48,038,935	35,894,823	34,337,591
Accumulated deficit	(37,943,582)	$ (24,135,447)	(12,346,630)
Accumulated other comprehensive loss	(64,238)
Total Stockholders' Equity- Less Non-Controlling Interest	10,032,480	$ 11,760,358	21,991,922
Non-Controlling Interest	(1,278,361)	(729,171)	(274,777)
Total Stockholders' Equity - Heat Biologics, Inc.	8,754,119	11,031,187	21,717,145
Total Liabilities and Stockholders' Equity	$ 16,662,528	$ 15,916,170	$ 23,020,066
Series 1 Preferred Stock [Member]
Stockholders' Equity
Total Stockholders' Equity - Heat Biologics, Inc.
Series A Preferred Stock [Member]
Stockholders' Equity
Total Stockholders' Equity - Heat Biologics, Inc.
Series B-1 Preferred Stock [Member]
Stockholders' Equity
Total Stockholders' Equity - Heat Biologics, Inc.

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Common stock, par value per share	$ 0.0002	$ 0.0002	$ 0.0002
Common stock, shares authorized	50,000,000	50,000,000	50,000,000
Common stock, shares issued	8,415,434	6,492,622	6,375,426
Common stock, shares outstanding	8,415,434	6,492,622	6,375,426

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Operating expenses:
Research and development	$ 677,151	$ 1,025,442	$ 1,767,942	$ 2,425,404	$ 2,861,231	$ 2,737,688
Clinical and regulatory	3,718,902	1,258,566	9,261,529	3,218,137	5,348,091	1,397,157
General and administrative	947,392	832,101	3,150,394	2,844,883	3,977,605	2,429,796
Total operating expenses	5,343,445	3,116,109	14,179,865	8,488,424	12,186,927	6,564,641
Loss from operations	(5,343,445)	(3,116,109)	(14,179,865)	(8,488,424)	(12,186,927)	(6,564,641)
Interest income					40,570	10,068
Interest income	20,121	9,740	49,970	27,261
Other income (expense)	4,449	(12,762)	29,909	(39,291)	(23,500)	23,828
Interest expense	(108,834)	(8,138)	(257,339)	(8,138)	(73,354)	(79,119)
Total non-operating (expenses) income	(84,264)	(11,160)	(177,460)	(20,168)	(56,284)	(45,223)
Net loss	(5,427,709)	(3,127,269)	(14,357,325)	(8,508,592)	(12,243,211)	(6,609,864)
Net loss - non-controlling interest	(242,244)	(126,865)	(549,190)	(330,675)	$ (454,394)	(198,516)
Beneficial conversion charge						(2,300,000)
Preferred stock dividend						(361,668)
Net loss attributable to Heat Biologics, Inc.	$ (5,185,465)	$ (3,000,404)	$ (13,808,135)	$ (8,177,917)	$ (11,788,817)	$ (9,073,016)
Net loss per share attributable to Heat Biologics, Inc.-basic and diluted	$ (0.62)	$ (0.46)	$ (1.75)	$ (1.27)	$ (1.83)	$ (2.42)
Weighted-average number of common shares used in net loss per share attributable to common stockholders - basic and diluted	8,408,376	6,469,272	7,880,637	6,445,129	6,454,866	3,747,357
Net loss	$ (5,427,709)	$ (3,127,269)	$ (14,357,325)	$ (8,508,592)	$ (12,243,211)	$ (6,609,864)
Other comprehensive loss:
Unrealized loss on foreign currency translation	(27,244)		(64,238)
Total comprehensive loss	(5,454,953)	$ (3,127,269)	(14,421,563)	$ (8,508,592)
Comprehensive loss attributable to non-controlling interest	(242,244)	(126,865)	(549,190)	(330,675)
Comprehensive loss - Heat Biologics, Inc.	$ (5,212,709)	$ (3,000,404)	$ (13,872,373)	$ (8,177,917)

Consolidated Statement of Stock

Consolidated Statement of Stockholders Equity - USD ($)	Total	Series 1 Preferred Stock [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Common Stock [Member]	APIC [Member]	Accumulated Deficit [Member]	Non-Controlling Interest [Member]	Accumulated Other Comprehensive Loss [Member]
Balance at Dec. 31, 2012	$ (1,515,109)	$ 11	$ 186		$ 405	$ 4,495,832	$ (5,935,282)	$ (76,261)
Preferred Stock Issued	$ 5,050,090			$ 189		5,049,901
Common Stock Issued: Preferred Series 1 Converted to Common Stock		$ (11)				11
Common Stock Issued: Preferred Series A Converted to Common Stock			$ (186)			186
Common Stock Issued: Preferred Series B Converted to Common Stock				$ (189)		189
Common Stock Issued	$ 25,110,540				$ 540	25,110,000
Exercise of stock options	$ 54,042				$ 16	$ 54,026
Common Stock Issued: Vesting of restricted stock
Common Stock Issued: Preferred Stock Dividend
Stock based compensation	$ 571,924					$ 571,924
Stock issuance costs	(944,478)					$ (944,478)
Net loss	(6,609,864)						$ (6,411,348)	$ (198,516)
Balance at Dec. 31, 2013	21,717,145				$ 961	$ 34,337,591	$ (12,346,630)	$ (274,777)
Exercise of stock options	$ 37,936				$ 13	$ 37,923
Cashless exercise of options
Cashless exercise of warrants	$ 452,874				$ 8	$ 452,866
Stock based compensation	1,066,443					$ 1,066,443
Net loss	(12,243,211)						$ (11,788,817)	$ (454,394)
Balance at Dec. 31, 2014	11,031,187				$ 982	$ 35,894,823	$ (24,135,447)	$ (729,171)
Common Stock Issued	$ 11,400,870				$ 377	$ 11,400,493
Exercise of stock options
Common Stock Issued: Vesting of restricted stock					$ 6	$ (6)
Stock based compensation	$ 1,046,086					1,046,086
Stock issuance costs	(302,461)					$ (302,461)
Accumulated other comprehensive loss	(64,238)								$ (64,238)
Net loss	(14,357,325)						$ (13,808,135)	$ (549,190)
Balance at Sep. 30, 2015	$ 8,754,119				$ 1,365	$ 48,038,935	$ (37,943,582)	$ (1,278,361)	$ (64,238)

Consolidated Statement of Stoc6

Consolidated Statement of Stockholders Equity (Parenthetical) - $ / shares	1 Months Ended		9 Months Ended	12 Months Ended
	Jul. 31, 2013	Mar. 31, 2013	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013	Mar. 25, 2013
Equity Issuance [Line Items]
Issuance of preferred stock, shares	2,500,000
Exercise of options, shares			10,272	78,664	80,706
Common Stock [Member]
Equity Issuance [Line Items]
Issuance of preferred stock, shares			1,886,000		2,700,000
Exercise of stock options, shares				66,707	80,706
Common Stock Issued: Vesting of restricted stock, shares					2,899
Cashless exercise of options, shares				10,442
Cashless exercise of warrants, shares				40,047
Exercise of options, shares			6,812
Vesting of restricted stock, shares			30,000
Preferred Stock [Member]
Equity Issuance [Line Items]
Common Stock Issued: Preferred Series 1 Converted to Common Stock, shares	49,960
Common Stock Issued: Preferred Series A Converted to Common Stock, shares	810,057
Common Stock Issued: Preferred Series B Converted to Common Stock, shares	836,666
Common Stock Issued: Preferred Stock Dividend, shares	36,167
Series B Preferred Stock [Member]
Equity Issuance [Line Items]
Preferred Stock Issued, shares		1,891,419
Share Price						$ 2.67

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Cash Flows from Operating Activities
Net loss	$ (14,357,325)	$ (8,508,592)	$ (12,243,211)	$ (6,609,864)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	84,373	41,850	66,895	6,348
Amortization of debt issuance costs	75,818	13,848	37,556	28,229
Amortization of bond premium	$ 102,618	137,897	173,204	50,781
Re-measurement of fair value of stock warrants liability		7,263	7,263	30,440
Stock based compensation	$ 1,046,086	722,358	1,066,443	571,924
Increase (decrease) in cash arising from changes in assets and liabilities:
Related party receivable	(9,375)	(18,446)	(23,696)	(15,375)
Prepaid expenses and other current assets	(157,440)	318,275	203,411	(1,008,202)
Restricted cash			(99,877)	$ 24,962
Deposits	(50,000)	(10,478)	(10,478)
Accounts payable	(385,161)	28,561	715,509	$ 146,446
Accrued expenses and other payables	1,260,355	$ (56,888)	302,918	373,842
Other long term liabilities	$ 12,228
Accrued interest		$ (25,364)	(25,364)	11,601
Net Cash Used in Operating Activities	$ (12,377,823)	(7,349,716)	(9,829,427)	$ (6,388,868)
Cash Flows from Investing Activities
Proceeds from maturities of short term investments	14,943,468	13,827,773	18,623,826
Purchases of short term investments	(11,090,091)	(8,783,623)	(12,198,847)	$ (17,347,946)
Purchases of property and equipment	(106,838)	(452,444)	(458,676)	(49,319)
Net Cash Provided by Investing Activities	3,746,539	$ 4,591,706	$ 5,966,303	(17,397,265)
Cash Flows from Financing Activities
Initial public offering price				$ 25,110,000
Proceeds from long term debt, net			$ 2,972,500
Payments on notes payable				$ (925,000)
Issuance of convertible notes payable, net of issuance costs				(197,099)
Proceeds from March 2015 public offering, net of underwriting discounts	$ 11,400,870			540
Proceeds from the exercise of stock options		$ 37,719	$ 37,936	54,042
Proceeds from issuance of long term debt	$ 2,242,575	$ 1,435,283		200,000
Payments on long term debt	(145,161)
Stock issuance costs	(302,461)			(944,478)
Net Cash Provided by Financing Activities	13,195,823	$ 1,473,002	$ 3,010,436	28,348,095
Effect of exchange rate changes on cash and cash equivalents	(67,905)
Net (Decrease) Increase in Cash and Cash Equivalents	4,496,634	$ (1,285,008)	(852,688)	4,561,962
Cash and Cash Equivalents - Beginning of Period	3,714,304	4,566,992	4,566,992	5,030
Cash and Cash Equivalents - End of Period	8,210,938	3,281,984	3,714,304	4,566,992
Supplemental Disclosure for Cash Flow Information
Interest paid	$ 257,339	8,138	$ 32,025	60,922
Supplemental Schedule of Noncash Investing and Financing Activities
Beneficial conversion charge				2,300,000
Non-cash conversion of preferred stock into common stock				386
Preferred conversion of preferred stock into common stock				$ 361,668
Cashless exercise of stock warrants		$ 452,874	$ 452,874
Issuance of warrants			$ 323,021
Series B-1 Preferred Stock [Member]
Cash Flows from Operating Activities
Net loss
Cash Flows from Financing Activities
Issuance of preferred stock				$ 5,050,090
Series A Preferred Stock [Member]
Cash Flows from Operating Activities
Net loss

Organization

Organization	12 Months Ended
	Dec. 31, 2014
Organization [Abstract]
Organization	1. Organization Heat Biologics, Inc. (“Heat” or “the Company”), was incorporated in 2008 pursuant to the laws of the state of Delaware. Heat Biologics, Inc. is a development stage company focused on the development and commercialization of ImPact™ Heat owns 92.5 its subsidiary, Heat Biologics I, Inc. On May 30, 2012, Heat formed two-wholly owned subsidiaries, Heat Biologics III, Inc. (“Heat III”) and Heat Biologics, IV, Inc. (“Heat IV”). Heat formed Heat Biologics GmbH (Heat GmbH), a wholly-owned limited liability company, organized in Germany on September 11, 2012. Heat also formed Heat Biologics Australia Pty LTD, a wholly-owned proprietary company, registered in Australia on March 14, 2014. Heat's product candidates require clinical trials and approvals from regulatory agencies, as well as acceptance in the marketplace. Part of Heat's strategy is to develop and commercialize some of its product candidates by continuing existing arrangements with academic and corporate collaborators and licensees and by entering into new collaborations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying unaudited consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial reporting. However, certain information or footnote disclosures normally included in complete financial statements prepared in accordance with U.S. GAAP have been condensed, or omitted, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). In the opinion of the Company's management, the unaudited consolidated financial statements in this Quarterly Report on Form 10-Q include all normal and recurring adjustments necessary for the fair statement of the results for the interim periods presented. The results for the three months and nine months ended September 30, 2015 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2015. The consolidated financial statements as of and for the three and nine months ended September 30, 2015 and 2014 included in this Quarterly Report on Form 10-Q are unaudited. The balance sheet as of December 31, 2014 is derived from the audited consolidated financial statements as of that date. The accompanying unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes, together with Management's Discussion and Analysis of Financial Condition and Results of Operations, contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC on March 27, 2015 (the “2014 Annual Report”). The accompanying consolidated financial statements as of and for the three and nine months ended September 30, 2015 and 2014 include the accounts of Heat Biologics, Inc. and its subsidiaries, Heat Biologics I, Inc. (“Heat I”), Heat Biologics III, Inc. (“Heat III”), Heat Biologics IV, Inc. (“Heat IV”), Heat Biologics GmbH and Heat Biologics Australia Pty Ltd. The functional currency of the entities located outside the United States of America (the foreign entities) is the applicable local currency. Assets and liabilities of the foreign entities are translated at period-end exchange rates. Statement of operations accounts are translated at the average exchange rate during the period. The effects of foreign currency translation adjustments are included in other comprehensive loss, which is a component of accumulated other comprehensive loss in stockholders' equity. All significant intercompany accounts and transactions have been eliminated in consolidation. At December 31, 2014 and September 30, 2015, Heat Biologics, Inc. held a 92.5 The accompanying consolidated financial statements have been prepared on a going concern basis. The Company has an accumulated a deficit of approximately $ 37.9 14.4 In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”). ASU 2015-03 revises Subtopic 835-30 to require that debt issuance costs be reported in the balance sheet as a direct deduction from the face amount of the related liability, consistent with the presentation of debt discounts. Prior to the amendments, debt issuance costs were presented as a deferred charge (i.e., an asset) on the balance sheet. The ASU provides examples illustrating the balance sheet presentation of notes net of their related discounts and debt issuance costs. Further, the amendments require the amortization of debt issuance costs to be reported as interest expense. Similarly, debt issuance costs and any discount or premium are considered in the aggregate when determining the effective interest rate on the debt. The amendments are effective for public business entities for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The amendments are effective for all other entities for fiscal years beginning after December 15, 2015, and interim periods within fiscal years beginning after December 15, 2016. The amendments must be applied retrospectively. All entities have the option of adopting the new requirements as of an earlier date for financial statements that have not been previously issued. The Company does not expect this ASU to have a material impact on its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (“ASU 2014-15”). The amendments in ASU 2014-15 are intended to define management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. Under U.S. GAAP, financial statements are prepared under the presumption that the reporting organization will continue to operate as a going concern, except in limited circumstances. The going concern basis of accounting is critical to financial reporting because it establishes the fundamental basis for measuring and classifying assets and liabilities. Currently, U.S. GAAP lacks guidance about management's responsibility to evaluate whether there is substantial doubt about the organization's ability to continue as a going concern or to provide related footnote disclosures. This ASU provides guidance to an organization's management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes. This update is effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016. Early application is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. The Company does not expect this ASU to have a significant impact on its consolidated financial statements.	2. Summary of Significant Accounting Policies Basis of Accounting The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Principles of Consolidation The consolidated financial statements include the accounts of Heat Biologics, Inc. and its subsidiaries, Heat Biologics I, Inc. (“Heat I”) Heat Biologics III, Inc. (“Heat III”), Heat Biologics IV, Inc. (“Heat IV”), Heat Biologics GmbH and Heat Biologics Australia Pty Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation. At December 31, 2014 and 2013, Heat held a 92.5 Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates are used for, but not limited to, useful lives of fixed assets, income taxes and stock-based compensation. Actual results may differ from those estimates. Cash and Cash Equivalents and Restricted Cash The Company considers all cash and other highly liquid investments with initial maturities from the date of purchase of three months or less to be cash and cash equivalents. The Company had a restricted cash balance of $ 101,129 1,252 1,000 100,000 Concentration of Credit Risk At times, cash balances may exceed the Federal Deposit Insurance Corporation (“FDIC”) insurable limits. The Company has never experienced any losses related to these balances. As of December 31, 2014 and 2013, cash amounts in excess of $ 250,000 3,704,026 Deferred Financing Costs, net Deferred financing costs, net include the costs incurred to obtain financing and are amortized using the straight-line method, which approximates the effective interest method, over the life of the related debt. Deferred financing costs, net are included in the accompanying consolidated balance sheets net of amortization. Property and Equipment Property and equipment are stated at cost and are capitalized if the cost exceeds $ 500 five seven Stock Warrants Liability In 2012 and 2013, the Company issued warrants exercisable for a total of 20,549 In connection with the Square 1 Bank Loan (“Loan”), in August 2014, the Company issued Square 1 Bank a warrant, exercisable for 52,695 4.27 Distinguishing Liabilities from Equity 323,021 17,664 The fair value of the warrants was calculated using the Black-Scholes option pricing model with the following assumptions: December 31, 2014 2013 Risk-free interest rate 2.23 2.46 % 2.75 % Expected volatility 73.0 100 % 71.6 71.9 % Expected life (years) 7.8 10 7.96 8.6 Expected dividend yield 0 % 0 % The Company had no stock warrant liability as of December 31, 2014. Beneficial Conversion Feature When the Company issues an equity security that is convertible into common stock at a discount from the fair value of the common stock at the date the equity security counterparty is legally committed to purchase such a security (Commitment Date), a beneficial conversion charge is measured and recorded on the Commitment Date for the difference between the fair value of the Company's common stock and the effective conversion price of the equity security. If the intrinsic value of the beneficial conversion feature is greater than the proceeds allocated to the equity security, the amount of the discount assigned to the beneficial conversion feature is limited to the amount of the proceeds allocated to the equity. The amount allocated to the beneficial conversion feature is presented as an immediate charge to earnings available to common stockholders for convertible preferred stock instruments that are convertible by the stockholders at any time. In connection with the Company's issuance of Series B-1 Preferred Stock during fiscal year 2013, the Company recorded a beneficial conversion charge of $ 2.3 6.14 8.81 Net Loss per Share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during each year. Fully diluted net loss per share is computed using the weighted average number of common shares and dilutive securities outstanding during each year. Dilutive securities having an anti-dilutive effect on diluted loss per share are excluded from the calculation. Fair Value of Financial Instruments The carrying amount of certain of the Company's financial instruments, including cash and cash equivalents, prepaid expenses and other current assets, deposits, accounts payable and accrued expenses and other payables approximate fair value due to their short maturities. The carrying value of debt approximates fair value because the interest rate under the obligation approximates market rates of interest available to the Company for similar instruments. As a basis for determining the fair value of certain of the Company's financial instruments, the Company utilizes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level I – Observable inputs such as quoted prices in active markets for identical assets or liabilities. Level II – Observable inputs, other than Level I prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level III – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company's financial instruments that are measured at fair value on a recurring basis consist only of the stock warrants liability. The Company's stock warrants liability was classified within Level III of the fair value hierarchy and as of December 31, 2014 and 2013. The change in the fair value of the Level III warrants liability is summarized below: Fair value at December 31, 2012 $ 92,150 Change in fair value during the period 30,440 Fair value at December 31, 2013 122,590 Issuance of new warrants 323,021 Change in fair value during the period 7,263 Cashless exercise during the period (452,874 ) Fair value at December 31, 2014 $ — There were no assets or liabilities measured at fair value on a recurring basis as of December 31, 2014. The liabilities measured at fair value on a recurring basis as of December 31, 2013 are summarized below: December 31, 2013 Identical Assets Observable Inputs Unobservable Inputs Total December 31, Description (Level 1) (Level 2) (Level 3) 2013 Liabilities measured at fair value Stock Warrant Liability $ — $ — $ (122,590 ) $ (122,590 ) Total Liabilities measured at fair value $ — $ — $ (122,590 ) $ (122,590 ) Marketing Marketing costs are expensed as incurred. Marketing expense totaled $ 135,372 135,366 Income Tax Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of assets and liabilities and their respective tax bases, operating loss carryforwards, and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. In accordance with FASB ASC 740, Accounting for Income Taxes Stock-Based Compensation The Company accounts for stock-based compensation arrangements with employees and non-employee directors using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments, including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option pricing model. Stock-based compensation costs are based on the fair value of the underlying option calculated using the Black-Scholes-Merton option pricing model on the date of grant for stock options and recognized as expense on a straight-line basis over the requisite service period, which is the vesting period. Determining the appropriate fair value model and related assumptions requires judgment, including estimating stock price volatility, forfeiture rates and expected term. The expected volatility rates are estimated based on the actual volatility of comparable public companies over the expected term. The expected term for the years ended December 31, 2014 and 2013 represents the average time that options are expected to be outstanding based on the mid-point between the vesting date and the end of the contractual term of the award. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company has not paid dividends and does not anticipate paying a cash dividend in the foreseeable future and, accordingly, uses an expected dividend yield of zero. The risk-free interest rate is based on the rate of U.S. Treasury securities with maturities consistent with the estimated expected term of the awards. The measurement of nonemployee share-based compensation is subject to periodic adjustments as the underlying equity instruments vest and is recognized as an expense over the period over which services are received. Net loss attributable to non-controlling interests Net loss attributable to non-controlling interests is the result of the Company's consolidation of subsidiaries of which it does not own 100%. The Company's net loss attributable to non-controlling interests relates to the University's ownership in Heat I, for the years ended December 31, 2014 and 2013. Revenue Recognition The Company recognizes government grants when there is reasonable assurance that they will comply with the conditions attached to the grants and the grants will be received. The grants are recognized using an income approach and grant revenue is recognized as the related expenses are incurred. Research and Development Research and development costs are expensed as incurred. The Company has acquired exclusive licensing rights to intellectual property to further its research and development. These costs are expensed as incurred. The Company also incurs intellectual property costs relating to the filing and application fees for patents which are owned by the universities with which the Company has license agreements. These costs are also expensed as research and development expense as incurred. Impact of recently issued Accounting Standards: In July 2014, the FASB issued Accounting Standards Update (“ASU”) ASU No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation . The amendments in this ASU remove all incremental financial reporting requirements from U.S. GAAP for development stage entities, including the removal of Topic 915, Development Stage Entities, from the FASB Accounting Standards Codification™. A development stage entity is one that devotes substantially all of its efforts to establishing a new business and for which: (a) planned principal operations have not commenced; or (b) planned principal operations have commenced, but have produced no significant revenue. Current U.S. GAAP requires a development stage entity to present the same basic financial statements and apply the same recognition and measurement rules as established companies. In addition, U.S. GAAP requires a development stage entity to present inception-to-date information about income statement line items, cash flows, and equity transactions. For public business entities, the presentation and disclosure requirements in Topic 915 will no longer be required for the first annual period beginning after December 15, 2014. The revised consolidation standards are effective one year later, in annual periods beginning after December 15, 2015. Early adoption is permitted for financial statements that have not yet been issued or made available for issuance. The Company has elected to adopt the guidance as of June 30, 2014. The adoption did not impact the Company's financial position or results of operations. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (“ASU 2014-15”). The amendments in ASU 2014-15 are intended to define management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. Under GAAP, financial statements are prepared under the presumption that the reporting organization will continue to operate as a going concern, except in limited circumstances. The going concern basis of accounting is critical to financial reporting because it establishes the fundamental basis for measuring and classifying assets and liabilities. Currently, GAAP lacks guidance about management's responsibility to evaluate whether there is substantial doubt about the organization's ability to continue as a going concern or to provide related footnote disclosures. This ASU provides guidance to an organization's management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes. This update is effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016. Early application is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. We do not expect this ASU to have an impact on its consolidated financial statements. In January 2015, the FASB issued ASU No. 2015-1, Income Statement - Extraordinary and Unusual Items. ASU 2015-01 will eliminate from U.S. GAAP the concept of extraordinary items and will no longer require an entity to separately classify, present, and disclose extraordinary events and transactions. ASU 2015-01 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015, and early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. The Company does not believe the adoption of this guidance will have a material impact on its consolidated financial statements or related footnote disclosures.

Investments

Investments	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Investments [Abstract]
Investments	3. Investments Investments in certain securities may be classified into three categories: • Held-to-maturity - Debt securities that the Company has the positive intent and ability to hold to maturity are reported at amortized cost. • Trading securities - Debt and equity securities that are bought and held principally for the purpose of selling in the near term are reported at fair value with unrealized gains and losses included in earnings. • Available-for-sale - Debt and equity securities not classified as either securities held-to-maturity or trading securities are reported at fair value with unrealized gains or losses excluded from earnings and reported as a separate component of stockholders' equity. The Company reassesses the appropriateness of the classification of its investments at the end of each reporting period. The Company has determined that its debt securities should be classified as held-to-maturity as of September 30, 2015 and December 31, 2014. This classification was based upon management's determination that it has the positive intent and ability to hold the securities until their maturity dates, as the underlying cash invested in these securities is not required for current operations. Investments consist of short-term FDIC insured certificates of deposit, tri-party repurchase agreement (“repo”) collateralized by U.S. Treasuries and agencies, and corporate notes and bonds rated A and above carried at amortized cost using the effective interest method. The following table summarizes information about short term investments at December 31, 2014 and September 30, 2015, respectively: Amortized Cost Gross Unrealized (Losses) Estimated Fair Value December 31, 2014 Certificates of deposit, corporate notes and bonds $ 10,698,982 $ (2,209 ) $ 10,696,773 September 30, 2015 Certificates of deposit, tri-party repurchase agreement, corporate notes and bonds $ 6,742,987 $ (2,814 ) $ 6,740,173 As of September 30, 2015, the estimated fair value of the investments was less than the amortized cost. Because management has the positive intention and ability to hold the investments until their maturity dates, these unrealized losses were not recorded in the accompanying unaudited consolidated financial statements. The maturities of held-to-maturity investments at September 30, 2015 were as follows: Less than 1 Year Total Certificates of deposit, tri-party repurchase agreement, corporate notes and bonds $ 6,742,987 $ 6,742,987	3 . Investments Investments in certain securities may be classified into three categories: • Held-to-maturity - Debt securities that the Company has the positive intent and ability to hold to maturity are reported at amortized cost. • Trading securities - Debt and equity securities that are bought and held principally for the purpose of selling in the near term are reported at fair value with unrealized gains and losses included in earnings. • Available-for-sale - Debt and equity securities not classified as either securities held-to-maturity or trading securities are reported at fair value with unrealized gains or losses excluded from earnings and reported as a separate component of stockholders' equity. The Company reassesses the appropriateness of the classification of its investments at the end of each reporting period. The Company has determined that its debt securities should be classified as held-to-maturity as of December 31, 2014 and 2013. This classification was based upon management's determination that it has the positive intent and ability to hold the securities until their maturity dates, as the underlying cash invested in these securities is not required for current operations. Investments consist of short-term FDIC insured certificates of deposit, commercial paper rated A1/P1 or above and corporate notes and bonds rated A and above carried at amortized cost using the effective interest method. The following summarizes information about short term investments at December 31, 2014 and 2013, respectively: Amortized Cost Gross Unrealized (Losses) Estimated Fair Value 2014 Certificates of deposit, commercial paper $ 10,698,982 $ (2,209) $ 10,696,773 2013 Certificates of deposit, commercial paper $ 17,297,165 $ (16,493) $ 17,280,672 As of December 31, 2014 and 2013, the estimated fair value of the investments was less than the amortized cost. Because management intends to hold the investments until their maturity dates, these unrealized losses were not recorded in the consolidated financial statements. The maturities of held-to-maturity investments at December 31, 2014 and 2013, respectively were as follows: Less than 1 Year Total 2014 Certificates of deposit, commercial paper $ 10,698,982 $ 10,698,982 2013 Certificates of deposit, commercial paper $ 17,297,165 $ 17,297,165

Property and Equipment

Property and Equipment	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Property and Equipment [Abstract]
Property and Equipment	4. Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method, over the estimated useful lives, ranging generally from five seven for maintenance and repairs are charged to expense as incurred. Property and equipment consisted of the following: September 30, 2015 December 31, 2014 Furniture and fixtures $ 55,275 $ 50,391 Computers 32,485 24,174 Lab equipment 541,066 447,423 Total 628,826 521,988 Accumulated depreciation (160,827 ) (76,454 ) Property and equipment, net $ 467,999 $ 445,534 Depreciation expense was $ 30,436 22,952 84,373 41,850	4. Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method, over estimated useful lives, ranging generally from five seven Property and equipment consisted of the following at: December 31, 2014 2013 Furniture and fixtures $ 50,391 $ 10,780 Computers 24,174 13,175 Lab equipment 447,423 39,357 Total 521,988 63,312 Accumulated depreciation (76,454 ) (9,559 ) Property and equipment, net $ 445,534 $ 53,753 Depreciation expense totaled $ 66,895 6,348

Accrued Expenses and other paya

Accrued Expenses and other payables	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Accrued Expenses and other payables [Abstract]
Accrued Expenses and other payables	5. Accrued Expenses and other payables Accrued expenses and other payables consisted of the following: September 30, 2015 December 31, 2014 Patent fees $ 35,000 $ 40,000 Deferred rent 54,957 51,155 Compensation and related benefits 92,233 519,092 Accrued professional services fees 836,333 — Accrued clinical trial expense 1,055,651 195,721 $ 2,074,174 $ 805,968	5. Accrued Expenses Accrued expenses consist of the following at: December 31, 2014 2013 Compensation and related benefits $ 519,092 $ 356,588 Patent fees 40,000 40,000 Deferred 51,155 — Accrued clinical trial expense 195,721 106,462 $ 805,968 $ 503,050

Debt Issuance Costs

Debt Issuance Costs	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Debt Issuance Costs [Abstract]
Debt Issuance Costs	6. Debt Issuance Costs During 2014, the Company recorded $ 323,021 27,500 42 7,425 Total amortization expense for the debt issuance costs was $ 75,818 13,848	6. Debt Issuance Costs During 2014 the Company recorded $ 323,021 27,500 42 Total amortization expense for the debt issuance costs was $ 37,556 28,229

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Dec. 31, 2014
Convertible Notes Payable [Abstract]
Convertible Notes Payable	7. Convertible Notes Payable On October 20, 2011, the Company entered into a convertible note agreement with a vendor for an amount up to $ 950,000 12 The note is convertible into common or Series A preferred stock at the latest valuation. The type of security converted will depend on whether common or Series A preferred stock is issued as part of a successful future equity raise of at least $7.5 million at the qualified offering price. 197,099

Notes Payable

Notes Payable	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Notes Payable [Abstract]
Notes Payable	7. Notes Payable Square 1 Bank Loan In August 2014, the Company entered into a secured loan with Square 1 Bank (“Loan”). The Loan provides the Company with a term loan in the aggregate principal amount not to exceed $ 7,500,000 $ 1,500,000 1,500,000 2,250,000 2,250,000 1,500,000 2,250,000 5,250,000 s tranche by December 31, 2015 . The Loan accrues interest monthly at an interest rate at the greater of prime rate plus 3.05 6.30 145,161 0 83,090 181,520 0	8. Notes Payable On August 7, 2012, the Company entered into a loan and security agreement (“the Loan and Security Agreement”) with a bank. The terms of the agreement provide for a $ 1,000,000 3 6 thirty-six 225,000 5 4.25 725,000 On January 10, 2013, the Company signed a Second Amendment to its Loan and Security Agreement which granted an extension of credit in the form of a Non-Formula Revolving Line (“the Non-Formula Line”) for an amount up to $ 200,000 200,000 Non-Formula Non-Formula Non-Formula 200,000 Non-Formula In conjunction with the Loan and Security Agreement, the Company issued warrants to the bank to purchase 17,500 4.83 7,609 3,072 In August 2014, the Company entered into a secured loan with Square 1 Bank (“Loan”). The Loan provides the Company with a term loan in the aggregate principal amount not to exceed $ 7,500,000 1,500,000 1,500,000 2,250,000 ImPACT™ 2,250,000 1,500,000 3,000,000 The Loan accrues interest monthly at an interest rate of 3.05 6.30 0 24,150 In connection with the Loan, in August 2014, the Company issued Square 1 Bank a warrant, exercisable for 52,695 4.27 Distinguishing Liabilities from Equity 323,021 17,664 As of December 31, 2014 future principal payments under the Company's notes payable agreement are as follows: Years ending December 31, 2015 $ 397,465 2016 1,223,502 2017 1,223,502 2018 155,531 Total $ 3,000,000

License Agreements

License Agreements	12 Months Ended
	Dec. 31, 2014
License Agreements [Abstract]
License Agreements	9. License Agreements On July 11, 2008, Heat entered into two agreements with The University of Miami (the “University”) to license, from the University, certain technology and processes in various stages of patent pursuit on an exclusive basis for use in its research and development and commercial activities (“License Agreement 03-31, 05-39” and “License Agreement 97-14”, or collectively “License Agreements”). Heat has the right to grant sublicenses under the License Agreements. Heat is also responsible for all patent costs, past and future, associated with the preparation, filing, prosecution, issuance, and maintenance of United States patent applications. Heat is also required to make minimum royalty payments to the University under the terms of the License Agreements. In connection with the License Agreements, Heat agreed to issue to the University 10 In April 2009, Heat and the University agreed to amend the original License Agreements of July 11, 2008 to extend the terms of payments. For the additional consideration of $ 12,500 On June 26, 2009, Heat assigned all rights and obligations of License Agreement 97-14 to its subsidiary, Heat I. All previous stock ownership and rights of the University to participate in future stock offerings by Heat were mutually terminated. Heat I agreed to issue the University 5 2.5 7.5 10,000 20,000 250,000 In August 2009, Heat I and the University entered into a second amendment (“Amendment 2”) to License Agreement 97-14 to extend the foregoing payment due dates for all past due license fees and patent costs. On August 30, 2010, Heat entered into an option agreement with the University of Michigan (“University II”) to acquire the right to negotiate an exclusive license for certain materials which includes cancer bladder cells and all unmodified derivatives of these cells. An option fee of $ 2,000 10,000 On February 18, 2011, Heat I entered into a license agreement (“SS114A”) with the University to obtain additional technology related to License Agreement 97-14. Heat I agreed to reimburse the University for all past patent costs of $ 37,381 On February 18, 2011, Heat I entered into a license agreement (“143”) with the University to obtain additional technology related to License Agreement 97-14. In consideration for the license, Heat I agreed to pay the University a fee of $ 50,000 14,158 On February 18, 2011, Heat I entered into a license agreement (“J110”) with the University to obtain additional technology related to License Agreement 97-14. In consideration for the license, Heat I agreed to pay the University a fee of $ 10,000 1,055 On February 18, 2011, Heat I entered into a license agreement (“D-107”) with the University to obtain additional technology related to License Agreement 97-14. On April 12, 2011, Heat entered into a non-exclusive evaluation and biological material license agreement with a not-for-profit corporation for evaluation and production of vaccines. In consideration for the evaluation and commercial use license, Heat agreed to pay the not-for-profit corporation a fee of $ 5,000 50,000 At December 31, 2011, Heat owed the University $ 160,000 102,784 18 On September 23, 2014, Heat entered into an exclusive license agreement for a multiple myeloma cell line with Professor Kenneth Nilsson in Sweden. In consideration of the commercial license, Heat agreed to pay an up-front license fee of $ 5,000 3,000 30,000 In addition, Heat entered into an agreement with the University of Miami in September 2014 for a cancer cell line where the University agreed not to license the cell line to third parties while we are in good standing and in compliance of our patent license agreements with the University relating to our ImPACT™ Future minimum royalty payments as of December 31, 2014 are as follows: Year ended December 31, 2015 $ 33,000 2016 33,000 2017 283,000 2018 33,000 2019 33,000 Thereafter 99,000 Total $ 514,000

Stock Warrants Liability

Stock Warrants Liability	12 Months Ended
	Dec. 31, 2014
Stock Warrants Liability [Abstract]
Stock Warrants Liability	10. Stock Warrants Liability The summary of stock warrants liability activity for the years ended December 31, 2014 and 2013 is as follows: Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Weighted Average Fair Value Outstanding at December 31, 2012 20,549 $ 4.83 8.9 $ 1.64 Granted — — — — Exercised — — — — Expired/cancelled — — — — Outstanding at December 31, 2013 20,549 $ 4.83 8.2 $ 5.95 Granted 52,695 $ 4.27 10.0 $ 6.13 Exercised (73,244 ) $ 4.43 9.5 $ 6.08 Expired/cancelled — — — — Outstanding at December 31, 2014 — $ — — $ — The aggregate intrinsic value of the stock warrants in the table above is $ 0 46,646

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Stockholders' Equity [Abstract]
Stockholders' Equity	8. Stock-Based Compensation Restricted Stock During the three and nine month period ended September 30, 2015, the Company recognized $ 13,950 103,950 no 30, 2014. Common Stock Warrants On March 10, 2011, the Company issued warrants to purchase 32,610 0.48 10 years from the issuance date. In connection with our initial public offering, the Company issued warrants to the underwriters for 125,000 12.50 five As of September 30, 2015, the Company has warrants outstanding to purchase 17,392 0.48 125,000 12.50 Stock Options The following is a summary of the stock option activity for the nine months ended September 30, 2015: Shares Weighted Outstanding, December 31, 2014 1,018,590 $ 5.04 Granted 277,875 $ 6.09 Exercised (10,272 ) $ 1.97 Forfeited (179,298 ) $ 6.50 Outstanding, September 30, 2015 1,106,895 $ 5.10 The weighted average grant-date fair value of stock options granted during the nine months ended September 30, 2015 was $ 3.33 Dividend yield 0.0 % Expected volatility 83.62 % Risk-free interest rate 1.63 % Expected lives (years) 6.0 The risk-free interest rate is based on U.S. Treasury interest rates at the time of the grant whose term is consistent with the expected life of the stock options. The Company used an average historical stock price volatility based on an analysis of reported data for a peer group of comparable companies that have issued stock options with substantially similar terms, as the Company did not have sufficient trading history for its common stock. Expected term represents the period that the Company's stock option grants are expected to be outstanding. The Company elected to utilize the “simplified” method to estimate the expected term. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option. Expected dividend yield was considered to be 0% in the option pricing formula since the Company had not paid any dividends and had no plans to do so in the future. The forfeiture rate was considered to be none as the options vest on a monthly basis. The Company recognized $ 245,289 224,586 942,136 722,358 The following table summarizes information about stock options outstanding at September 30, 2015: Options Outstanding Options Vested and Exercisable Balance as of 9/30/2015 Weighted Contractual Weighted Balance Weighted Contractual Weighted 1,106,895 7.4 $ 5.10 649,421 6.2 $ 3.89 As of September 30, 2015, the unrecognized stock-based compensation expense related to unvested stock options was $ 3,114,452 15.8	11. Stockholders' Equity Authorized Capital Heat has authorized 10,000,000 0.0001 1,891,419 5.0 361,668 Heat had 50,000,000 0.0002 6,492,622 6,375,426 Preferred Stock Series A, Series B-1, and Series B-2 Automatic Conversion Each share of Preferred Stock automatically converts to common stock upon the earlier to occur of (i) on the date of consummation of a sale of common stock in a firm commitment underwritten public offering resulting in aggregate net cash proceeds to the Company (after deducting applicable underwriting discounts and commissions) of at least $ 15 Optional Conversion The preferred stock is convertible into common stock at the option of the holder at any time. The conversion ratio for each share of the Series A Preferred Stock was its Original Issue Price ($ 2.10 2.67 5.00 0.4348 In the event the Company at any time or from time to time after the Initial Series B Issuance Date shall issue additional shares of common stock without consideration or for consideration per share less than the Series A Conversion Price, Series B-1 Conversion Price, or Series B-2 Conversion Price, in effect on the date of and immediately prior to such issue, then the Series A Conversion Price, the Series B-1 Conversion Price, Series B-2 Conversion Price, shall be reduced, to a price determined by multiplying the Series A Conversion Price, the Series B-1 Conversion Price, or the Series B-2 Conversion Price in effect by a fraction, (A) the numerator of which shall be the number of shares of common stock outstanding immediately prior to such issuance, on a fully-diluted basis, plus the number of shares of common stock which the aggregate consideration received by the Company for the total number of Additional Shares of Common Stock so issued would purchase at the Series A Conversion Price, the Series B-1 Conversion Price, or the Series B-2 Conversion Price, as in effect immediately prior to such issuance, and (B) the denominator of which shall be the number of shares of common stock outstanding immediately prior to such issuance, on a fully-diluted basis, plus the number of such Additional Shares of common stock so issued. As a result of the IPO, all outstanding shares of preferred stock were automatically converted to common stock. The preferred stock was determined to have characteristics more akin to equity than debt. Particularly, the preferred stock had no mandatory redemption provision nor was it redeemable at the option of the holder. As a result, the conversion option was determined to be clearly and closely related to the preferred stock and therefore did not need to be bifurcated and classified as a liability. Dividends The Series B Preferred Stock has a priority with respect to dividend distributions and distributions upon liquidation. The Series B Preferred Stock receive dividends when and as and if declared by the Board at a rate of 5 6.14 11.50 Liquidation In the event of a liquidation, the holders of the Series B-1 and B-2 Preferred Stock are entitled to receive before any payment to any other Preferred Stockholder or common stock holder an amount per share equal to the greater of $ 6.14 11.50 4.83 Voting Rights Each holder of Preferred Stock is entitled to vote on all matters stockholders are entitled to vote and to cast the number of votes as shall equal the whole number of shares of common stock into which their shares of Preferred Stock are convertible. Initial Public Offering On July 29, 2013, the Company sold 2,500,000 10.00 25 22.4 100,000 10.00 1,000,000 930,000 100,000 10.00 1,000,000 930,000 27,000,000 24.3 1,696,683 36,167 Restricted Stock As of December 31, 2014 and 2013, all restricted stock has vested and accordingly all stock-based compensation expense related to vested restricted stock has been recognized. Common Stock Warrants In December 2011 and August 2012, the Company issued 20,549 10 4.83 8,065 On March 10, 2011, the Company issued warrants to purchase 32,610 0.48 15,218 14,318 In connection with our initial public offering, the Company issued warrants to the underwriters for 125,000 shares of common stock issuable at $ 12.50 five In connection with the Loan, in August 2014, the Company issued Square 1 Bank a warrant, exercisable for 52,695 4.27 17,664 The following table summarizes the activity of the Company's common stock warrants, retroactively adjusted for the 1-for-2.3 reverse stock split. Common Stock Warrants Outstanding, December 31, 2012 53,159 Granted to underwriters 125,000 Exercised — Expired — Outstanding, December 31, 2013 178,159 Granted to lenders 52,695 Exercised (88,462 ) Expired — Outstanding, December 31, 2014 142,392 The weighted average exercise price of 142,392 outstanding warrants as of December 31, 2014 is $ 11.03 Equity Compensation Plan 2009 Stock Incentive Plan In 2009, the Company adopted the 2009 Stock Option Plan of Heat Biologics, Inc. (the “2009 Plan”), under which stock options to acquire 217,391 common shares could be granted to key employees, directors, and independent contractors. Under the 2009 Plan, both incentive and non-qualified stock options could be granted under terms and conditions established by the Board of Directors. The exercise price for incentive stock options was the fair market value of the related common stock on the date the stock option was granted. Stock options granted under the 2009 Plan generally have terms of 10 The Company amended the 2009 Stock Option Plan and all related addendum agreements in April 2011. This second amendment increased the number of shares available for issuance from 217,391 652,174 869,565 581,842 633,482 2014 Stock Incentive Plan In June 2014, the stockholders approved the 2014 Stock Option Plan of Heat Biologics, Inc. (the “2014 Plan”), under which the Company is authorized to grant 500,000 10 The 2014 Plan supplements the Company's 2009 Stock Incentive Plan (the “2009 Plan”) under which the Company is authorized to grant 500,000 436,748 As of December 31, 2014, awards for 1,416,091 115,398 1,018,590 68,872 For the years ended December 31, 2014 2013 Employee stock options $ 570,760 $ 131,178 Non-employee stock options 495,683 415,212 Restricted stock awards — 25,534 $ 1,066,443 $ 571,924 Stock Options The fair value of each stock option is estimated on the date of grant using the Black-Scholes-Merton option pricing model with the following assumptions for stock options granted during the years ended: December 31, 2014 2013 Dividend yield 0.0 % 0.0 % Expected volatility 107 110 % 90 112 % Risk-free interest rate 2.06 2.23 % 1.39 2.26 % Expected lives (years) 5.9 6.5 5.75 6.5 The risk-free interest rate is based on U.S. Treasury interest rates at the time of the grant whose term is consistent with the expected life of the stock options. The Company used an average historical stock price volatility based on an analysis of reported data for a peer group of comparable companies that have issued stock options with substantially similar terms, as the Company did not have any trading history for its common stock. Expected term represents the period that the Company's stock option grants are expected to be outstanding. The Company elected to utilize the “simplified” method to estimate the expected term. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option. Expected dividend yield was considered to be 0% in the option pricing formula since the Company had not paid any dividends and had no plans to do so in the future. The forfeiture rate was considered to be none insofar as the historical experience of the Company is very limited. As required by ASC 718, the Company will adjust the estimated forfeiture rate based upon actual experience. The Company recognized $ 1,066,443 571,924 The following tables summarize the stock option activity for the years ended December 31, 2013 and 2014: Shares Weighted Exercise Outstanding, December 31, 2012 590,047 $ 0.71 Granted 186,736 $ 10.07 Exercised (80,706 ) $ 0.67 Forfeited (62,595 ) $ 1.96 Outstanding, December 31, 2013 633,482 $ 3.36 Granted 507,879 $ 6.30 Exercised (78,664 ) $ 0.60 Forfeited (44,107 ) $ 3.19 Outstanding, December 31, 2014 1,018,590 $ 5.04 The weighted average grant-date fair value of stock options granted during the years ended December 31, 2014 and 2013 was $ 5.66 8.51 The total fair value of stock options that vested during the year ended December 31, 2014 was approximately $ 1,704,121 The following table summarizes information about stock options outstanding at December 31, 2014: Options Outstanding Options Exercisable Options Vested or Expected to Vest Balance as of 12/31/2014 Weighted Average Remaining Contractual Life (Years) Weighted Balance Weighted Weighted Balance Weighted Weighted 1,018,590 7.81 $ 5.04 473,696 5.99 $ 2.67 473,696 5.99 $ 2.67 As of December 31, 2014, the unrecognized stock-based compensation expense related to unvested stock options was approximately $ 3,872,221 14.9

Income Tax

Income Tax	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Income Tax [Abstract]
Income Tax	11. Income Tax Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases, operating loss carryforwards, and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. In accordance with FASB ASC 740, Accounting for Income Taxes , the Company reflects in the accompanying unaudited consolidated financial statements the benefit of positions taken in a previously filed tax return or expected to be taken in a future tax return only when it is considered ‘more-likely-than-not' that the position taken will be sustained by a taxing authority. As of September 30, 2015 and December 31, 2014, the Company had no unrecognized income tax benefits and correspondingly there is no impact on the Company's effective income tax rate associated with these items. The Company's policy for recording interest and penalties relating to uncertain income tax positions is to record them as a component of income tax expense in the accompanying consolidated statements of operations and comprehensive loss. As of September 30, 2015 and December 31, 2014, the Company had no such accruals.	12. Income Tax The components of income tax expense (benefit) attributable to continuing operations are as follows: Years ended December 31, 2014 2013 Current expense: Federal $ — $ — State — — Deferred expense (benefit): Federal $ — $ — State — — Total $ — $ — The differences between the Company's consolidated income tax expense attributable to continuing operations and the expense computed at the 34 Years ended December 31, 2014 2013 Federal income tax expense at statutory rate $ (4,162,691 ) $ (2,247,353 ) State and local income taxes, net of federal benefit (344,247 ) (186,475 ) Non-deductible expenses 239,213 4,985 Prior-period true-up (161,018 ) 162,061 Research & development credit (454,031 ) (180,687 ) Change in tax rate — 32,774 Stock based compensation 135,008 — Increase in valuation allowance 4,747,766 2,414,695 $ — $ — The income tax effects of temporary differences from continuing operations that give rise to significant portions of deferred income tax assets (liabilities) are presented below: December 31, 2014 2013 Deferred tax assets: Net operating loss carryforward $ 8,141,857 $ 4,167,785 Research & development credit 961,445 424,739 Other 484,954 247,966 Valuation allowance (9,588,256 ) (4,840,490 ) Deferred income taxes $ — $ — During 2014, the Company's valuation allowance increased by $ 4,747,766 The Company has approximately $ 42,039,675 In accordance with FASB ASC 740, Accounting for Income Taxes The Company files income tax returns in the United States and various state jurisdictions. The Company is subject to examination by taxing authorities for the tax years ended December 31, 2008 through 2013.

Related Party

Related Party	12 Months Ended
	Dec. 31, 2014
Related Party [Abstract]
Related Party	13. Related Party A member of the Company's management was paid $ 28,000 34,480 The Company compensates its board members. Board members received between $ 32,000 37,000 5,000 10,870 The Company had a related party payable balance of $ 26,750 13,000 The Company had a related party receivable balance of $ 48,642 24,946

Net Loss Per Share

Net Loss Per Share	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Net Loss Per Share [Abstract]
Net Loss Per Share	10. Net Loss Per Share Basic and diluted net loss per common share is calculated by dividing net loss applicable to Heat Biologics, Inc. by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. The Company's potentially dilutive shares, which include outstanding stock options and warrants, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. The following table reconciles net loss to net loss attributable to Heat Biologics, Inc.: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Net loss $ (5,427,709 ) $ (3,127,269 ) $ (14,357,325 ) $ (8,508,592 ) Net loss: Non-controlling interest (242,244 ) (126,865 ) (549,190 ) (330,675 ) Net loss attributable to Heat Biologics, Inc. $ (5,185,465 ) $ (3,000,404 ) $ (13,808,135 ) $ (8,177,917 ) Weighted-average number of common shares used in net loss per share attributable to Heat Biologics, Inc.—basic and diluted 8,408,376 6,469,272 7,880,637 6,445,129 Net loss per share attributable to Heat Biologics, Inc.—basic and diluted $ (0.62 ) $ (0.46 ) $ (1.75 ) $ (1.27 ) The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect: For the Nine Months Ended September 30, 2015 2014 Outstanding stock options 1,106,895 836,961 Common stock warrants 17,392 17,392 Underwriters warrants 125,000 125,000	14. Net Loss Per Share Basic net loss per common share is computed by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the periods. Fully diluted net loss per common share is computed using the weighted average number of common and dilutive common equivalent shares outstanding during the periods. Common equivalent shares consist of stock options and warrants that are computed using the treasury stock method. For the years ended December 31, 2014 and 2013, all of the Company's common stock options and warrants are anti-dilutive and therefore have been excluded from the diluted calculation. The following table reconciles net loss to net loss applicable to common stockholders: For the years ended December 31, 2014 2013 Net loss $ (12,243,211 ) $ (6,609,864 ) Net loss: Non-controlling interest (454,394 ) (198,516 ) Beneficial conversion charge — (2,300,000 ) Preferred Stock Dividend — (361,668 ) Net loss applicable to common stockholders $ (11,788,817 ) $ (9,073,016 ) Weighted-average number of common shares used in net loss per share applicable to common stockholders—basic and diluted 6,454,866 3,747,357 Net loss per share applicable to common stockholders—basic and diluted $ (1.83 ) $ (2.42 ) The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect): For the years ended December 31, 2014 2013 Outstanding stock options 1,018,590 633,482 Common stock warrants 142,392 178,159 Reverse Stock Split In May 2013, the Company's board of directors and stockholders approved a 1-for-2.3 reverse stock split of the Company's common stock. The reverse stock split became effective on May 29, 2013. All share and per share amounts in the financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split, including reclassifying an amount equal to the increase in par value to additional paid-in capital.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies [Abstract]
Commitments and Contingencies	15. Commitments and Contingencies On January 24, 2014 the Company entered into a five 10,341 11,638 4,046 100,973 48,377 Years ending December 31, 2015 $ 192,833 2016 218,271 2017 224,282 2018 231,010 2019 194,401 Total $ 1,060,797

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	16. Subsequent Events Departure of Certain Officers and Appointment of Certain Officers On March 9, 2015 the Company entered into a Severance Agreement (the “Severance Agreement”) with Matthew Czajkowski, the Company's Chief Financial Officer effective March 15, 2015. The complete terms of the Severance Agreement is filed as Exhibit 10.1 to Form 8-K filed March 11, 2015. Mr. Czajkowski has the ability to exercise all stock options issued to him that vested prior to the date of resignation at any time prior to the ten 90 On March 9, 2015, the Company entered into a consulting agreement (the “Consulting Agreement”) with Danforth Advisors, LLC (“Danforth”), pursuant to which Danforth will provide finance, accounting and administrative functions, including interim chief financial officer services to be provided by Mr. Stephen J. DiPalma. The Company will pay Danforth an agreed upon hourly rate for such services and will reimburse Danforth for expenses. The Consulting Agreement will continue until December 31, 2015 and may be extended by mutual agreement of the parties. The Consulting Agreement may be terminated by the Company with cause immediately and without cause, upon 30 Public Offering On March 10, 2015, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”) with Aegis Capital Corp. (“Aegis”), as representative of the several underwriters named therein (the “Underwriters”), providing for the offer and sale in a firm commitment underwritten public offering (the “Offering”) of 1,640,000 246,000 6.50 11.1

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2015
Fair Value of Financial Instruments [Abstract]
Fair Value of Financial Instruments	2. Fair Value of Financial Instruments The carrying amount of certain of the Company's financial instruments, including cash and cash equivalents, restricted cash, accounts payable and accrued expenses and other payables approximate fair value due to their short maturities. The carrying value of debt approximates fair value because the interest rate under the obligation approximates market rates of interest available to the Company for similar instruments. As a basis for determining the fair value of certain of the Company's financial instruments, the Company utilizes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level I – Observable inputs such as quoted prices in active markets for identical assets or liabilities. Level II – Observable inputs, other than Level I prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level III – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company's assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. The majority of the Company's cash equivalents and investments are classified within Level II of the fair value hierarchy.

Financing

Financing	9 Months Ended
	Sep. 30, 2015
Financing [Abstract]
Financing	9. Financing Public Offering On March 10, 2015, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”) with Aegis Capital Corp. (“Aegis”), as representative of the several underwriters named therein (the “Underwriters”), providing for the offer and sale in a firm commitment underwritten public offering (the “Offering”) of 1,640,000 246,000 6.50 11.1

Summary of Significant Accoun26

Summary of Significant Accounting Policies (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Summary of Significant Accounting Policies [Abstract]
Basis of Accounting	The accompanying unaudited consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial reporting. However, certain information or footnote disclosures normally included in complete financial statements prepared in accordance with U.S. GAAP have been condensed, or omitted, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). In the opinion of the Company's management, the unaudited consolidated financial statements in this Quarterly Report on Form 10-Q include all normal and recurring adjustments necessary for the fair statement of the results for the interim periods presented. The results for the three months and nine months ended September 30, 2015 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2015. The consolidated financial statements as of and for the three and nine months ended September 30, 2015 and 2014 included in this Quarterly Report on Form 10-Q are unaudited. The balance sheet as of December 31, 2014 is derived from the audited consolidated financial statements as of that date. The accompanying unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes, together with Management's Discussion and Analysis of Financial Condition and Results of Operations, contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC on March 27, 2015 (the “2014 Annual Report”).	Basis of Accounting The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
Principles of Consolidation	The accompanying consolidated financial statements as of and for the three and nine months ended September 30, 2015 and 2014 include the accounts of Heat Biologics, Inc. and its subsidiaries, Heat Biologics I, Inc. (“Heat I”), Heat Biologics III, Inc. (“Heat III”), Heat Biologics IV, Inc. (“Heat IV”), Heat Biologics GmbH and Heat Biologics Australia Pty Ltd. The functional currency of the entities located outside the United States of America (the foreign entities) is the applicable local currency. Assets and liabilities of the foreign entities are translated at period-end exchange rates. Statement of operations accounts are translated at the average exchange rate during the period. The effects of foreign currency translation adjustments are included in other comprehensive loss, which is a component of accumulated other comprehensive loss in stockholders' equity. All significant intercompany accounts and transactions have been eliminated in consolidation. At December 31, 2014 and September 30, 2015, Heat Biologics, Inc. held a 92.5 The accompanying consolidated financial statements have been prepared on a going concern basis. The Company has an accumulated a deficit of approximately $ 37.9 14.4 In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”). ASU 2015-03 revises Subtopic 835-30 to require that debt issuance costs be reported in the balance sheet as a direct deduction from the face amount of the related liability, consistent with the presentation of debt discounts. Prior to the amendments, debt issuance costs were presented as a deferred charge (i.e., an asset) on the balance sheet. The ASU provides examples illustrating the balance sheet presentation of notes net of their related discounts and debt issuance costs. Further, the amendments require the amortization of debt issuance costs to be reported as interest expense. Similarly, debt issuance costs and any discount or premium are considered in the aggregate when determining the effective interest rate on the debt. The amendments are effective for public business entities for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The amendments are effective for all other entities for fiscal years beginning after December 15, 2015, and interim periods within fiscal years beginning after December 15, 2016. The amendments must be applied retrospectively. All entities have the option of adopting the new requirements as of an earlier date for financial statements that have not been previously issued. The Company does not expect this ASU to have a material impact on its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (“ASU 2014-15”). The amendments in ASU 2014-15 are intended to define management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. Under U.S. GAAP, financial statements are prepared under the presumption that the reporting organization will continue to operate as a going concern, except in limited circumstances. The going concern basis of accounting is critical to financial reporting because it establishes the fundamental basis for measuring and classifying assets and liabilities. Currently, U.S. GAAP lacks guidance about management's responsibility to evaluate whether there is substantial doubt about the organization's ability to continue as a going concern or to provide related footnote disclosures. This ASU provides guidance to an organization's management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes. This update is effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016. Early application is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. The Company does not expect this ASU to have a significant impact on its consolidated financial statements.	Principles of Consolidation The consolidated financial statements include the accounts of Heat Biologics, Inc. and its subsidiaries, Heat Biologics I, Inc. (“Heat I”) Heat Biologics III, Inc. (“Heat III”), Heat Biologics IV, Inc. (“Heat IV”), Heat Biologics GmbH and Heat Biologics Australia Pty Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation. At December 31, 2014 and 2013, Heat held a 92.5
Use of Estimates		Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates are used for, but not limited to, useful lives of fixed assets, income taxes and stock-based compensation. Actual results may differ from those estimates.
Cash and Cash Equivalents and Restricted Cash		Cash and Cash Equivalents and Restricted Cash The Company considers all cash and other highly liquid investments with initial maturities from the date of purchase of three months or less to be cash and cash equivalents. The Company had a restricted cash balance of $ 101,129 1,252 1,000 100,000
Concentration of Credit Risk		Concentration of Credit Risk At times, cash balances may exceed the Federal Deposit Insurance Corporation (“FDIC”) insurable limits. The Company has never experienced any losses related to these balances. As of December 31, 2014 and 2013, cash amounts in excess of $ 250,000 3,704,026
Deferred Financing Costs, net		Deferred Financing Costs, net Deferred financing costs, net include the costs incurred to obtain financing and are amortized using the straight-line method, which approximates the effective interest method, over the life of the related debt. Deferred financing costs, net are included in the accompanying consolidated balance sheets net of amortization.
Property and Equipment		Property and Equipment Property and equipment are stated at cost and are capitalized if the cost exceeds $ 500 five seven
Stock Warrants Liability		Stock Warrants Liability In 2012 and 2013, the Company issued warrants exercisable for a total of 20,549 In connection with the Square 1 Bank Loan (“Loan”), in August 2014, the Company issued Square 1 Bank a warrant, exercisable for 52,695 4.27 Distinguishing Liabilities from Equity 323,021 17,664 The fair value of the warrants was calculated using the Black-Scholes option pricing model with the following assumptions: December 31, 2014 2013 Risk-free interest rate 2.23 2.46 % 2.75 % Expected volatility 73.0 100 % 71.6 71.9 % Expected life (years) 7.8 10 7.96 8.6 Expected dividend yield 0 % 0 % The Company had no stock warrant liability as of December 31, 2014.
Beneficial Conversion Feature		Beneficial Conversion Feature When the Company issues an equity security that is convertible into common stock at a discount from the fair value of the common stock at the date the equity security counterparty is legally committed to purchase such a security (Commitment Date), a beneficial conversion charge is measured and recorded on the Commitment Date for the difference between the fair value of the Company's common stock and the effective conversion price of the equity security. If the intrinsic value of the beneficial conversion feature is greater than the proceeds allocated to the equity security, the amount of the discount assigned to the beneficial conversion feature is limited to the amount of the proceeds allocated to the equity. The amount allocated to the beneficial conversion feature is presented as an immediate charge to earnings available to common stockholders for convertible preferred stock instruments that are convertible by the stockholders at any time. In connection with the Company's issuance of Series B-1 Preferred Stock during fiscal year 2013, the Company recorded a beneficial conversion charge of $ 2.3 6.14 8.81
Net Loss per Share		Net Loss per Share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during each year. Fully diluted net loss per share is computed using the weighted average number of common shares and dilutive securities outstanding during each year. Dilutive securities having an anti-dilutive effect on diluted loss per share are excluded from the calculation.
Fair Value of Financial Instruments		Fair Value of Financial Instruments The carrying amount of certain of the Company's financial instruments, including cash and cash equivalents, prepaid expenses and other current assets, deposits, accounts payable and accrued expenses and other payables approximate fair value due to their short maturities. The carrying value of debt approximates fair value because the interest rate under the obligation approximates market rates of interest available to the Company for similar instruments. As a basis for determining the fair value of certain of the Company's financial instruments, the Company utilizes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level I – Observable inputs such as quoted prices in active markets for identical assets or liabilities. Level II – Observable inputs, other than Level I prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level III – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company's financial instruments that are measured at fair value on a recurring basis consist only of the stock warrants liability. The Company's stock warrants liability was classified within Level III of the fair value hierarchy and as of December 31, 2014 and 2013. The change in the fair value of the Level III warrants liability is summarized below: Fair value at December 31, 2012 $ 92,150 Change in fair value during the period 30,440 Fair value at December 31, 2013 122,590 Issuance of new warrants 323,021 Change in fair value during the period 7,263 Cashless exercise during the period (452,874 ) Fair value at December 31, 2014 $ — There were no assets or liabilities measured at fair value on a recurring basis as of December 31, 2014. The liabilities measured at fair value on a recurring basis as of December 31, 2013 are summarized below: December 31, 2013 Identical Assets Observable Inputs Unobservable Inputs Total December 31, Description (Level 1) (Level 2) (Level 3) 2013 Liabilities measured at fair value Stock Warrant Liability $ — $ — $ (122,590 ) $ (122,590 ) Total Liabilities measured at fair value $ — $ — $ (122,590 ) $ (122,590 )
Marketing		Marketing Marketing costs are expensed as incurred. Marketing expense totaled $ 135,372 135,366
Income Tax		Income Tax Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of assets and liabilities and their respective tax bases, operating loss carryforwards, and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. In accordance with FASB ASC 740, Accounting for Income Taxes
Stock-Based Compensation		Stock-Based Compensation The Company accounts for stock-based compensation arrangements with employees and non-employee directors using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments, including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option pricing model. Stock-based compensation costs are based on the fair value of the underlying option calculated using the Black-Scholes-Merton option pricing model on the date of grant for stock options and recognized as expense on a straight-line basis over the requisite service period, which is the vesting period. Determining the appropriate fair value model and related assumptions requires judgment, including estimating stock price volatility, forfeiture rates and expected term. The expected volatility rates are estimated based on the actual volatility of comparable public companies over the expected term. The expected term for the years ended December 31, 2014 and 2013 represents the average time that options are expected to be outstanding based on the mid-point between the vesting date and the end of the contractual term of the award. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company has not paid dividends and does not anticipate paying a cash dividend in the foreseeable future and, accordingly, uses an expected dividend yield of zero. The risk-free interest rate is based on the rate of U.S. Treasury securities with maturities consistent with the estimated expected term of the awards. The measurement of nonemployee share-based compensation is subject to periodic adjustments as the underlying equity instruments vest and is recognized as an expense over the period over which services are received.
Net loss attributable to non-controlling interests		Net loss attributable to non-controlling interests Net loss attributable to non-controlling interests is the result of the Company's consolidation of subsidiaries of which it does not own 100%. The Company's net loss attributable to non-controlling interests relates to the University's ownership in Heat I, for the years ended December 31, 2014 and 2013.
Revenue Recognition		Revenue Recognition The Company recognizes government grants when there is reasonable assurance that they will comply with the conditions attached to the grants and the grants will be received. The grants are recognized using an income approach and grant revenue is recognized as the related expenses are incurred.
Research and Development		Research and Development Research and development costs are expensed as incurred. The Company has acquired exclusive licensing rights to intellectual property to further its research and development. These costs are expensed as incurred. The Company also incurs intellectual property costs relating to the filing and application fees for patents which are owned by the universities with which the Company has license agreements. These costs are also expensed as research and development expense as incurred.
Impact of recently issued Accounting Standards		Impact of recently issued Accounting Standards: In July 2014, the FASB issued Accounting Standards Update (“ASU”) ASU No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation . The amendments in this ASU remove all incremental financial reporting requirements from U.S. GAAP for development stage entities, including the removal of Topic 915, Development Stage Entities, from the FASB Accounting Standards Codification™. A development stage entity is one that devotes substantially all of its efforts to establishing a new business and for which: (a) planned principal operations have not commenced; or (b) planned principal operations have commenced, but have produced no significant revenue. Current U.S. GAAP requires a development stage entity to present the same basic financial statements and apply the same recognition and measurement rules as established companies. In addition, U.S. GAAP requires a development stage entity to present inception-to-date information about income statement line items, cash flows, and equity transactions. For public business entities, the presentation and disclosure requirements in Topic 915 will no longer be required for the first annual period beginning after December 15, 2014. The revised consolidation standards are effective one year later, in annual periods beginning after December 15, 2015. Early adoption is permitted for financial statements that have not yet been issued or made available for issuance. The Company has elected to adopt the guidance as of June 30, 2014. The adoption did not impact the Company's financial position or results of operations. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (“ASU 2014-15”). The amendments in ASU 2014-15 are intended to define management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. Under GAAP, financial statements are prepared under the presumption that the reporting organization will continue to operate as a going concern, except in limited circumstances. The going concern basis of accounting is critical to financial reporting because it establishes the fundamental basis for measuring and classifying assets and liabilities. Currently, GAAP lacks guidance about management's responsibility to evaluate whether there is substantial doubt about the organization's ability to continue as a going concern or to provide related footnote disclosures. This ASU provides guidance to an organization's management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes. This update is effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016. Early application is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. We do not expect this ASU to have an impact on its consolidated financial statements. In January 2015, the FASB issued ASU No. 2015-1, Income Statement - Extraordinary and Unusual Items. ASU 2015-01 will eliminate from U.S. GAAP the concept of extraordinary items and will no longer require an entity to separately classify, present, and disclose extraordinary events and transactions. ASU 2015-01 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015, and early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. The Company does not believe the adoption of this guidance will have a material impact on its consolidated financial statements or related footnote disclosures.

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Summary of Significant Accounting Policies [Abstract]
Schedule of Significant Assumptions	December 31, 2014 2013 Risk-free interest rate 2.23 2.46 % 2.75 % Expected volatility 73.0 100 % 71.6 71.9 % Expected life (years) 7.8 10 7.96 8.6 Expected dividend yield 0 % 0 %
Schedule of Change in Fair Value of Level III Stock Warrants Liability	Fair value at December 31, 2012 $ 92,150 Change in fair value during the period 30,440 Fair value at December 31, 2013 122,590 Issuance of new warrants 323,021 Change in fair value during the period 7,263 Cashless exercise during the period (452,874 ) Fair value at December 31, 2014 $ —
Schedule of Major Categories of Assets and Liabilities Measured at Fair Value on Recurring Basis	December 31, 2013 Identical Assets Observable Inputs Unobservable Inputs Total December 31, Description (Level 1) (Level 2) (Level 3) 2013 Liabilities measured at fair value Stock Warrant Liability $ — $ — $ (122,590 ) $ (122,590 ) Total Liabilities measured at fair value $ — $ — $ (122,590 ) $ (122,590 )

Investments (Tables)

Investments (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Investments [Abstract]
Schedule of Held-To-Maturity Investments Estimated Fair Value of Investments	Amortized Cost Gross Unrealized (Losses) Estimated Fair Value December 31, 2014 Certificates of deposit, corporate notes and bonds $ 10,698,982 $ (2,209 ) $ 10,696,773 September 30, 2015 Certificates of deposit, tri-party repurchase agreement, corporate notes and bonds $ 6,742,987 $ (2,814 ) $ 6,740,173	Amortized Cost Gross Unrealized (Losses) Estimated Fair Value 2014 Certificates of deposit, commercial paper $ 10,698,982 $ (2,209) $ 10,696,773 2013 Certificates of deposit, commercial paper $ 17,297,165 $ (16,493) $ 17,280,672
Schedule of Maturities of Held-To-Maturity Investments	Less than 1 Year Total Certificates of deposit, tri-party repurchase agreement, corporate notes and bonds $ 6,742,987 $ 6,742,987	Less than 1 Year Total 2014 Certificates of deposit, commercial paper $ 10,698,982 $ 10,698,982 2013 Certificates of deposit, commercial paper $ 17,297,165 $ 17,297,165

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Property and Equipment [Abstract]
Schedule of Property and Equipment	September 30, 2015 December 31, 2014 Furniture and fixtures $ 55,275 $ 50,391 Computers 32,485 24,174 Lab equipment 541,066 447,423 Total 628,826 521,988 Accumulated depreciation (160,827 ) (76,454 ) Property and equipment, net $ 467,999 $ 445,534	December 31, 2014 2013 Furniture and fixtures $ 50,391 $ 10,780 Computers 24,174 13,175 Lab equipment 447,423 39,357 Total 521,988 63,312 Accumulated depreciation (76,454 ) (9,559 ) Property and equipment, net $ 445,534 $ 53,753

Accrued Expenses and other pa30

Accrued Expenses and other payables (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Accrued Expenses and other payables [Abstract]
Accrued Expenses and other payables	September 30, 2015 December 31, 2014 Patent fees $ 35,000 $ 40,000 Deferred rent 54,957 51,155 Compensation and related benefits 92,233 519,092 Accrued professional services fees 836,333 — Accrued clinical trial expense 1,055,651 195,721 $ 2,074,174 $ 805,968	December 31, 2014 2013 Compensation and related benefits $ 519,092 $ 356,588 Patent fees 40,000 40,000 Deferred 51,155 — Accrued clinical trial expense 195,721 106,462 $ 805,968 $ 503,050

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2014
Notes Payable [Abstract]
Schedule of future principal payments under notes payable agreement	Years ending December 31, 2015 $ 397,465 2016 1,223,502 2017 1,223,502 2018 155,531 Total $ 3,000,000

License Agreements (Tables)

License Agreements (Tables)	12 Months Ended
	Dec. 31, 2014
License Agreements [Abstract]
Schedule of Future Minimum Royalty Payments	Year ended December 31, 2015 $ 33,000 2016 33,000 2017 283,000 2018 33,000 2019 33,000 Thereafter 99,000 Total $ 514,000

Stock Warrants Liability (Table

Stock Warrants Liability (Tables)	12 Months Ended
	Dec. 31, 2014
Stock Warrants Liability [Abstract]
Summary of Stock Warrants Liability Activity	Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Weighted Average Fair Value Outstanding at December 31, 2012 20,549 $ 4.83 8.9 $ 1.64 Granted — — — — Exercised — — — — Expired/cancelled — — — — Outstanding at December 31, 2013 20,549 $ 4.83 8.2 $ 5.95 Granted 52,695 $ 4.27 10.0 $ 6.13 Exercised (73,244 ) $ 4.43 9.5 $ 6.08 Expired/cancelled — — — — Outstanding at December 31, 2014 — $ — — $ —

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Stockholders' Equity [Abstract]
Summary of Activity of Common Stock Warrants Retroactively Adjusted for Reverse Stock Split		Common Stock Warrants Outstanding, December 31, 2012 53,159 Granted to underwriters 125,000 Exercised — Expired — Outstanding, December 31, 2013 178,159 Granted to lenders 52,695 Exercised (88,462 ) Expired — Outstanding, December 31, 2014 142,392
Schedule of Components of Stock-based Compensation Included in Net Loss		For the years ended December 31, 2014 2013 Employee stock options $ 570,760 $ 131,178 Non-employee stock options 495,683 415,212 Restricted stock awards — 25,534 $ 1,066,443 $ 571,924
Schedule of Stock Option Valuation Assumptions	Dividend yield 0.0 % Expected volatility 83.62 % Risk-free interest rate 1.63 % Expected lives (years) 6.0	December 31, 2014 2013 Dividend yield 0.0 % 0.0 % Expected volatility 107 110 % 90 112 % Risk-free interest rate 2.06 2.23 % 1.39 2.26 % Expected lives (years) 5.9 6.5 5.75 6.5
Schedule of Stock Option Activity	Shares Weighted Outstanding, December 31, 2014 1,018,590 $ 5.04 Granted 277,875 $ 6.09 Exercised (10,272 ) $ 1.97 Forfeited (179,298 ) $ 6.50 Outstanding, September 30, 2015 1,106,895 $ 5.10	Shares Weighted Exercise Outstanding, December 31, 2012 590,047 $ 0.71 Granted 186,736 $ 10.07 Exercised (80,706 ) $ 0.67 Forfeited (62,595 ) $ 1.96 Outstanding, December 31, 2013 633,482 $ 3.36 Granted 507,879 $ 6.30 Exercised (78,664 ) $ 0.60 Forfeited (44,107 ) $ 3.19 Outstanding, December 31, 2014 1,018,590 $ 5.04
Schedule of Options Outstanding, Exercisable, and Vested or Expected to Vest	Options Outstanding Options Vested and Exercisable Balance as of 9/30/2015 Weighted Contractual Weighted Balance Weighted Contractual Weighted 1,106,895 7.4 $ 5.10 649,421 6.2 $ 3.89	Options Outstanding Options Exercisable Options Vested or Expected to Vest Balance as of 12/31/2014 Weighted Average Remaining Contractual Life (Years) Weighted Balance Weighted Weighted Balance Weighted Weighted 1,018,590 7.81 $ 5.04 473,696 5.99 $ 2.67 473,696 5.99 $ 2.67

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax [Abstract]
Schedule of Components of Income Tax Expense	Years ended December 31, 2014 2013 Current expense: Federal $ — $ — State — — Deferred expense (benefit): Federal $ — $ — State — — Total $ — $ —
Schedule of Income Tax Rate Reconciliation	Years ended December 31, 2014 2013 Federal income tax expense at statutory rate $ (4,162,691 ) $ (2,247,353 ) State and local income taxes, net of federal benefit (344,247 ) (186,475 ) Non-deductible expenses 239,213 4,985 Prior-period true-up (161,018 ) 162,061 Research & development credit (454,031 ) (180,687 ) Change in tax rate — 32,774 Stock based compensation 135,008 — Increase in valuation allowance 4,747,766 2,414,695 $ — $ —
Schedule of Deferred Tax Assets and Liabilities	December 31, 2014 2013 Deferred tax assets: Net operating loss carryforward $ 8,141,857 $ 4,167,785 Research & development credit 961,445 424,739 Other 484,954 247,966 Valuation allowance (9,588,256 ) (4,840,490 ) Deferred income taxes $ — $ —

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Net Loss Per Share [Abstract]
Schedule of Net Loss Per Share	Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Net loss $ (5,427,709 ) $ (3,127,269 ) $ (14,357,325 ) $ (8,508,592 ) Net loss: Non-controlling interest (242,244 ) (126,865 ) (549,190 ) (330,675 ) Net loss attributable to Heat Biologics, Inc. $ (5,185,465 ) $ (3,000,404 ) $ (13,808,135 ) $ (8,177,917 ) Weighted-average number of common shares used in net loss per share attributable to Heat Biologics, Inc.—basic and diluted 8,408,376 6,469,272 7,880,637 6,445,129 Net loss per share attributable to Heat Biologics, Inc.—basic and diluted $ (0.62 ) $ (0.46 ) $ (1.75 ) $ (1.27 )	For the years ended December 31, 2014 2013 Net loss $ (12,243,211 ) $ (6,609,864 ) Net loss: Non-controlling interest (454,394 ) (198,516 ) Beneficial conversion charge — (2,300,000 ) Preferred Stock Dividend — (361,668 ) Net loss applicable to common stockholders $ (11,788,817 ) $ (9,073,016 ) Weighted-average number of common shares used in net loss per share applicable to common stockholders—basic and diluted 6,454,866 3,747,357 Net loss per share applicable to common stockholders—basic and diluted $ (1.83 ) $ (2.42 )
Schedule of Potentially Dilutive Securities	For the Nine Months Ended September 30, 2015 2014 Outstanding stock options 1,106,895 836,961 Common stock warrants 17,392 17,392 Underwriters warrants 125,000 125,000	For the years ended December 31, 2014 2013 Outstanding stock options 1,018,590 633,482 Common stock warrants 142,392 178,159

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Years ending December 31, 2015 $ 192,833 2016 218,271 2017 224,282 2018 231,010 2019 194,401 Total $ 1,060,797

Organization (Details)

Organization (Details) - shares	Mar. 10, 2015	Sep. 30, 2013	Aug. 31, 2013	Jul. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Noncontrolling Interest [Line Items]
Common stock issued	1,640,000	100,000	100,000	2,500,000
Heat Biologics I, Inc [Member]
Noncontrolling Interest [Line Items]
Ownership interest in subsidiary					92.50%	92.50%

Summary of Significant Accoun39

Summary of Significant Accounting Policies (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Aug. 31, 2014	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Capitalized Costs Property And Equipment						$ 500
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted cash						101,129	$ 1,252
Minimum cash balance to pay trademark fees						1,000
Minimum cash balance with lending bank						100,000
Cash balance insured						250,000	250,000
Cash balance uninsured						$ 3,704,026
Debt Instrument, Convertible, Beneficial Conversion Feature							$ (2,300,000)
Effective conversion price, per share							$ 6.14
Fair value, per share							$ 8.81
Marketing Expense						$ 135,372	$ 135,366
Accumulated deficit		$ (37,943,582)		$ (37,943,582)		(24,135,447)	(12,346,630)
Net loss		$ (5,427,709)	$ (3,127,269)	$ (14,357,325)	$ (8,508,592)	$ (12,243,211)	$ (6,609,864)
Secured Loan - Square 1 Bank [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock issuable through warrants								52,695
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 4.27
Heat Biologics One [Member]
Noncontrolling Interest [Line Items]
Ownership interest in subsidiary		92.50%		92.50%		92.50%
Heat Biologics I, Inc [Member]
Noncontrolling Interest [Line Items]
Ownership interest in subsidiary						92.50%	92.50%
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life						7 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life						5 years
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock issuable through warrants							20,549		20,549
Debt discount						$ 323,021
Number of shares issued from cashless exercise of warrant	17,664
Warrant [Member] | Secured Loan - Square 1 Bank [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Debt discount						$ 323,021		$ 323,021

Summary of Significant Accoun40

Summary of Significant Accounting Policies (Assumptions Used in Valuation of Warrants) (Details) - Stock Warrants Liability [Member]	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate		2.75%
Dividend yield	0.00%	0.00%
Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	2.23%
Expected volatility	73.00%	71.60%
Expected lives	7 years 9 months 18 days	7 years 11 months 16 days
Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	2.46%
Expected volatility	100.00%	71.90%
Expected lives	10 years	8 years 7 months 6 days

Summary of Significant Accoun41

Summary of Significant Accounting Policies (Schedule of Change in Fair Value of the Level III Common Stock Warrant Liability ) (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Summary of Significant Accounting Policies [Abstract]
Fair value of stock warrant liability, beginning		$ 122,590	$ 122,590	$ 92,150
Cashless exercises during the period			323,021
Change in fair value during the period			7,263	$ 30,440
Cashless exercise during the period		$ (452,874)	$ (452,874)
Fair value of stock warrant liability, ending				$ 122,590

Summary of Significant Accoun42

Summary of Significant Accounting Policies (Schedule of Changes In Fair Value of Level III Stock Warrants Liability) (Details) - Fair Value, Measurements, Recurring [Member]	Dec. 31, 2013USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock warrants liability	$ (122,590)
Total Liabilities measured at fair value	$ (122,590)
Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock warrants liability
Total Liabilities measured at fair value
Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock warrants liability
Total Liabilities measured at fair value
Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock warrants liability	$ (122,590)
Total Liabilities measured at fair value	$ (122,590)

Investments (Schedule of Held-T

Investments (Schedule of Held-To-Maturity Investments) (Details) - Certificates of deposit, tri-party repurchase agreement, corporate notes and bonds [Member] - USD ($)	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Schedule of Trading Securities and Other Trading Assets [Line Items]
Amortized Cost	$ 6,742,987	$ 10,698,982	$ 17,297,165
Gross Unrealized (Losses)	(2,814)	(2,209)	(16,493)
Estimated Fair Value	6,740,173	10,696,773	17,280,672
Less than 1 year	6,742,987	10,698,982	17,297,165
Total	$ 6,742,987	$ 10,698,982	$ 17,297,165

Property and Equipment (Schedul

Property and Equipment (Schedule of Property and Equipment ) (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Total	$ 628,826		$ 628,826		$ 521,988	$ 63,312
Accumulated depreciation	(160,827)		(160,827)		(76,454)	(9,559)
Property and equipment, net	467,999		467,999		445,534	53,753
Depreciation	30,436	$ 22,952	$ 84,373	$ 41,850	$ 66,895	6,348
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives			5 years		5 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives			7 years		7 years
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Total	55,275		$ 55,275		$ 50,391	10,780
Estimated useful lives					7 years
Computers [Member]
Property, Plant and Equipment [Line Items]
Total	32,485		32,485		$ 24,174	13,175
Estimated useful lives					5 years
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Total	$ 541,066		$ 541,066		$ 447,423	$ 39,357
Estimated useful lives					5 years

Accrued Expenses and other pa45

Accrued Expenses and other payables (Schedule of Accrued Expenses) (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Accrued Expenses and other payables [Abstract]
Compensation and related benefits	$ 92,233	$ 519,092	$ 356,588
Patent fees	35,000	40,000	$ 40,000
Deferred Rent	54,957	$ 51,155
Accrued professional services fees	836,333
Accrued clinical trial expense	1,055,651	$ 195,721	$ 106,462
Accrued expenses	$ 2,074,174	$ 805,968	$ 503,050

Debt Issuance Costs (Narrative)

Debt Issuance Costs (Narrative) (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Aug. 31, 2014
Debt Instrument [Line Items]
Amortization of debt issuance costs	$ 75,818	$ 13,848	$ 37,556	$ 28,229
Warrant [Member]
Debt Instrument [Line Items]
Debt discount			323,021
Secured Loan - Square 1 Bank [Member]
Debt Instrument [Line Items]
Deferred financing cost	$ 7,425		$ 27,500
Debt Instrument, Term			42 months
Secured Loan - Square 1 Bank [Member] | Warrant [Member]
Debt Instrument [Line Items]
Debt discount			$ 323,021		$ 323,021

Convertible Notes Payable (Narr

Convertible Notes Payable (Narrative) (Details) - USD ($)	1 Months Ended
	Jul. 31, 2013	Oct. 31, 2011	Dec. 31, 2014	Dec. 31, 2013	Oct. 20, 2011
Debt Instrument [Line Items]
Debt instrument, carrying amount					$ 950,000
Interest rate					12.00%
Debt conversion description		The note is convertible into common or Series A preferred stock at the latest valuation. The type of security converted will depend on whether common or Series A preferred stock is issued as part of a successful future equity raise of at least $7.5 million at the qualified offering price.
Maturity date		Oct. 31, 2019
Accrued interest				$ 25,364
Payments on convertible notes payable	$ 197,099

Notes Payable (Narrative) (Deta

Notes Payable (Narrative) (Details)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2014shares

Aug. 31, 2013USD ($)

Jul. 31, 2013

Jan. 31, 2013

Aug. 31, 2012$ / shares

Dec. 31, 2011

Oct. 31, 2011

Sep. 30, 2015USD ($)

Sep. 30, 2014USD ($)

Sep. 30, 2015USD ($)

Sep. 30, 2014USD ($)

Dec. 31, 2014USD ($)

Aug. 31, 2014USD ($)$ / sharesshares

Feb. 28, 2014shares

Dec. 31, 2013shares

Dec. 14, 2013

Jan. 10, 2013USD ($)

Dec. 31, 2012shares

Aug. 07, 2012USD ($)shares

Oct. 20, 2011USD ($)

Debt Instrument [Line Items]

Debt instrument, face amount

$ 950,000

Maturity date

Oct. 31, 2019

Reverse stock split, conversion ratio

0.4348

Warrant [Member]

Debt Instrument [Line Items]

Number of shares of common stock issuable through warrants | shares

20,549

20,549

Debt discount

$ 323,021

Number of shares issued from cashless exercise of warrant | shares

17,664

Secured Loan - Square 1 Bank [Member]

Debt Instrument [Line Items]

Debt instrument, amount outstanding

$ 5,250,000

$ 5,250,000

Term of loan

42 months

Number of shares of common stock issuable through warrants | shares

52,695

Debt instrument, minimum interest rate

3.05%

3.05%

Debt instrument, maximum interest rate

6.30%

6.30%

Repayment of principal made during period

145,161

$ 145,161

$ 0

$ 0

$ 0

Interest paid during period

83,090

$ 0

181,520

$ 0

24,150

Exercise price of warrants | $ / shares

$ 4.27

Secured Loan - Square 1 Bank [Member] | Warrant [Member]

Debt Instrument [Line Items]

Debt discount

323,021

$ 323,021

Secured Loan - Square 1 Bank [Member] | Common Stock [Member]

Debt Instrument [Line Items]

Number of shares issued from cashless exercise of warrant | shares

17,664

Secured Loan - Square 1 Bank [Member] | Maximum [Member]

Debt Instrument [Line Items]

Debt instrument, face amount

$ 7,500,000

North Carolina Biotechnology Center Loan Agreement [Member]

Debt Instrument [Line Items]

Annual installments

5.00%

North Carolina Biotechnology Center Loan Agreement [Member] | Series A Preferred Stock [Member]

Debt Instrument [Line Items]

Warrant expiration date

Dec. 13, 2021

Loan And Security Agreement Tranche A [Member]

Debt Instrument [Line Items]

Debt instrument, face amount

$ 1,000,000

Accrues interest, annual

6.00%

Accrues interest, monthly

3.00%

Term of loan

36 months

Periodic payments, frequency

Monthly

Loan And Security Agreement Term Loan B [Member]

Debt Instrument [Line Items]

Annual installments

5.00%

5.00%

Accrues interest, annual

4.25%

Repayment of note payable and bank loan

$ 725,000

Loan And Security Agreement Term Loan B [Member] | Maximum [Member]

Debt Instrument [Line Items]

Debt instrument, face amount

$ 225,000

Loan And Security Agreement [Member]

Debt Instrument [Line Items]

Number Of Warrants Post Reverse Stock Split

7,609

Number of shares of common stock issuable through warrants | shares

3,072

Loan And Security Agreement [Member] | Series A Preferred Stock [Member]

Debt Instrument [Line Items]

Preferred stock shares purchased by warrant issued | shares

17,500

Exercise price of warrants | $ / shares

$ 4.83

Warrant expiration date

Aug. 7, 2022

Loan And Security Agreement Second Amendment [Member]

Debt Instrument [Line Items]

Outstanding loan

$ 200,000

Collateral amount

200,000

Maturity date

Jan. 9, 2014

Loan And Security Agreement Second Amendment [Member] | Maximum [Member]

Debt Instrument [Line Items]

Debt instrument, face amount

$ 200,000

Tranche 1 Loan [Member] | Secured Loan - Square 1 Bank [Member]

Debt Instrument [Line Items]

Debt instrument, face amount

$ 1,500,000

Debt instrument, amount outstanding

1,500,000

1,500,000

1,500,000

Tranche 2 Loan [Member] | Secured Loan - Square 1 Bank [Member]

Debt Instrument [Line Items]

Debt instrument, face amount

1,500,000

Debt instrument, amount outstanding

1,500,000

1,500,000

1,500,000

Tranche 3 Loan [Member] | Secured Loan - Square 1 Bank [Member]

Debt Instrument [Line Items]

Debt instrument, face amount

2,250,000

Debt instrument, amount outstanding

$ 2,250,000

$ 2,250,000

Tranche 3 Loan [Member] | Secured Loan - Square 1 Bank [Member] | Scenario, Forecast [Member]

Debt Instrument [Line Items]

Debt instrument, face amount

2,250,000

Tranche 4 Loan [Member] | Secured Loan - Square 1 Bank [Member]

Debt Instrument [Line Items]

Debt instrument, face amount

2,250,000

Tranche 4 Loan [Member] | Secured Loan - Square 1 Bank [Member] | Scenario, Forecast [Member]

Debt Instrument [Line Items]

Debt instrument, face amount

$ 2,250,000

Tranche 1 and 2 Loan [Member] | Secured Loan - Square 1 Bank [Member]

Debt Instrument [Line Items]

Debt instrument, amount outstanding

$ 3,000,000

Notes Payable (Schedule of Futu

Notes Payable (Schedule of Future Principal Payments Under Notes Payable Agreement) (Details)	Dec. 31, 2014USD ($)
Future principal payments
2,015	$ 397,465
2,016	1,223,502
2,017	1,223,502
2,018	155,531
Total	$ 3,000,000

License Agreements (Narrative)

License Agreements (Narrative) (Details) - USD ($)

Sep. 23, 2014

Jul. 31, 2011

Apr. 30, 2011

Feb. 28, 2011

Jun. 30, 2009

Apr. 30, 2009

Jul. 31, 2008

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

Dec. 31, 2013

May. 30, 2017

Dec. 31, 2011

Dec. 19, 2011

Sep. 08, 2010

Jun. 26, 2009

Additional consideration

$ 12,500

Minimum royalty payment for first three years, per year

$ 10,000

Minimum royalty payment for remainer life of agreement, per year

$ 20,000

Milestone payment

$ 250,000

Option fees

$ 2,000

Exercise of stock options

$ 10,000

$ 37,719

$ 37,936

$ 54,042

Unpaid License Fees

$ 160,000

Annual interest on outstanding balance

18.00%

University [Member]

Percentage of all issued and outstanding stock to be issued with license agreement

5.00%

2.50%

10.00%

Not for profit corporation fee one [Member]

License Costs

$ 5,000

Not for profit corporation fee two [Member]

License Costs

$ 50,000

License Agreement ("143") [Member]

Reimbursement of for past patent fees

$ 50,000

License Agreement ("143") [Member] | Patent [Member]

License Costs

14,158

License Agreement ("J110") [Member]

Reimbursement of for past patent fees

10,000

License Agreement ("J110") [Member] | Patent [Member]

License Costs

1,055

License agreement ("SS114A") [Member]

Reimbursement of for past patent fees

$ 37,381

License Agreement For Multiple Myeloma [Member]

License Costs

$ 5,000

Maintenance fee

3,000

License Agreement For Multiple Myeloma [Member] | Maximum [Member]

Maintenance fee

$ 30,000

Heat Biologics I, Inc [Member]

Unpaid License Fees

$ 102,784

Heat Biologics I, Inc [Member] | Not for profit corporation fee two [Member]

Percentage of issued and outstanding stock owned

7.50%

License Agreements (Schedule of

License Agreements (Schedule of Future Minimum Royalty Payments) (Details)	Dec. 31, 2014USD ($)
License Agreements [Abstract]
2,015	$ 33,000
2,016	33,000
2,017	283,000
2,018	33,000
2,019	33,000
Thereafter	99,000
Total	$ 514,000

Stock Warrants Liability (Detai

Stock Warrants Liability (Details) - Warrant [Member] - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Common Stock Warrants
Outstanding, beginning balance	20,549	20,549
Granted	52,695
Exercised	(73,244)
Expired/cancelled
Outstanding, ending balance		20,549	20,549
Weighted Average Exercise Price
Outstanding, at the beginning of year	$ 4.83	$ 4.83
Granted	4.27
Exercised	$ 4.43
Expired/cancelled
Outstanding, at the end of year		$ 4.83	$ 4.83
Weighted Average Remaining Contractual Life (in years)
Outstanding, beginning balance	0 years	8 years 2 months 12 days	8 years 10 months 24 days
Granted	10 years
Exercised	9 years 6 months
Outstanding, at the end of year	0 years	8 years 2 months 12 days	8 years 10 months 24 days
Weighted Average Fair Value
Outstanding, at the beginning of year	$ 5.95	$ 1.64
Granted	6.13
Exercised	$ 6.08
Expired/cancelled
Outstanding, at the end of year		$ 5.95	$ 1.64
Aggregate Intrinsic Value
Aggregate intrinsic value of preferred stock warrants	$ 0	$ 46,646

Stockholders' Equity (Deficit53

Stockholders' Equity (Deficit) (Narrative) (Details)	Mar. 10, 2015$ / sharesshares	Sep. 30, 2013USD ($)$ / sharesshares	Aug. 31, 2013USD ($)$ / sharesshares	Jul. 31, 2013USD ($)$ / sharesshares	Mar. 31, 2013USD ($)shares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2013USD ($)$ / sharesshares	Sep. 30, 2015$ / sharesshares
Stockholders' Equity [Abstract]
Common stock, par value per share | $ / shares						$ 0.0002	$ 0.0002	$ 0.0002
Common stock, shares authorized | shares						50,000,000	50,000,000	50,000,000
Common stock, shares issued | shares						6,492,622	6,375,426	8,415,434
Common stock, shares outstanding | shares						6,492,622	6,375,426	8,415,434
Offering price | $ / shares	$ 6.50	$ 10	$ 10	$ 10
Proceeds from initial public offering | $		$ 1,000,000	$ 1,000,000	$ 25,000,000		$ 27,000,000
Proceeds from initial public offering, net | $		$ 930,000	$ 930,000	$ 22,400,000		$ 24,300,000
Common stock issued for conversion of preferred stock | shares						1,696,683
Shares issued as stock dividend | shares						36,167
Preferred Stock Dividends, Income Statement Impact | $							$ 361,668
Class of Stock [Line Items]
Minimum net proceeds from public offering for automatic conversion | $						$ 15,000,000
Reverse stock split, conversion ratio						0.4348
Shares issuable upon conversion of preferred stock | shares						0.4348
Common stock issued | shares	1,640,000	100,000	100,000	2,500,000
Series 1 Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, liquidation preference | $ / shares						$ 4.83
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, par value per share | $ / shares						$ 0.001	$ 0.0001
Preferred stock, shares authorized | shares						2,000,000	10,000,000
Preferred stock, shares issued | shares							0
Preferred stock, shares outstanding | shares						0	0
Common stock, price per share | $ / shares						$ 2.10
Series B-1 Preferred Stock [Member]
Class of Stock [Line Items]
Common stock, price per share | $ / shares						$ 2.67
Preferred stock, dividend rate						5.00%
Preferred stock, dividend amount per share | $ / shares						$ 6.14
Preferred stock, liquidation preference | $ / shares						6.14
Proceeds from issuance of private placement | $					$ 5,000,000
Common stock issued | shares					1,891,419
Series B-2 Preferred Stock [Member]
Class of Stock [Line Items]
Common stock, price per share | $ / shares						$ 5
Preferred stock, dividend rate						5.00%
Preferred stock, dividend amount per share | $ / shares						$ 11.50
Preferred stock, liquidation preference | $ / shares						$ 11.50

Stockholders' Equity (Deficit54

Stockholders' Equity (Deficit) (Common Stock Warrants) (Details) - $ / shares	1 Months Ended		2 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Feb. 28, 2014	Feb. 28, 2014	Aug. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2011	Aug. 31, 2014
Secured Debt [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock issuable through warrants								52,695
Exercise price of warrants								$ 4.27
Common Stock Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock issuable through warrants		15,218	15,218	20,549
Exercise price of warrants				$ 4.83	$ 11.03	$ 12.50	$ 0.48
Expiration term				10 years		5 years	10 years
Exercise price							$ 0.48
Common stock, price per share						$ 12.50
Common Stock Warrants
Outstanding, beginning balance			178,159		178,159	53,159
Granted					52,695	125,000	32,610
Exercised					(88,462)
Expired
Outstanding, ending balance					142,392	178,159
Number of shares issued from cashless exercise of warrant		14,318	8,065
Common Stock Warrants [Member] | Secured Debt [Member]
Common Stock Warrants
Number of shares issued from cashless exercise of warrant	17,664

Stockholders' Equity (Deficit55

Stockholders' Equity (Deficit) (Equity Compensation Plan) (Narrative) (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended			12 Months Ended
	Jun. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Aug. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2011	Feb. 28, 2014	Dec. 31, 2012	Apr. 30, 2011	Dec. 31, 2009
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense				$ 1,046,086	$ 722,358		$ 1,066,443	$ 571,924
Outstanding stock options		1,106,895		1,106,895			1,018,590	633,482			590,047
Granted				277,875			507,879	186,736
Weighted average grant-date fair value				$ 3.33			$ 5.66	$ 8.51
Fair value of stock options vested							$ 1,704,121
Unrecognized stock-based compensation expense		$ 3,114,452		$ 3,114,452			$ 3,872,221
unrecognized stock-based compensation expense, recognition period				15 months 24 days			14 months 27 days
Warrants to Purchase Shares of Common Stock Issuable at Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants		$ 0.48		$ 0.48
Warrant liabilities outstanding		17,392		17,392
Warrants to Purchase Shares of Common Stock Issuable at Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants		$ 12.50		$ 12.50
Warrant liabilities outstanding		125,000		125,000
Common Stock Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted							52,695	125,000	32,610
Exercise price of warrants						$ 4.83	$ 11.03	$ 12.50	$ 0.48
Expiration term						10 years		5 years	10 years
Number of shares of common stock issuable through warrants						20,549				15,218
Restricted stock awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense								$ 25,534
Outstanding stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 245,289	$ 224,586	$ 942,136	$ 722,358		$ 570,760	$ 131,178
Non-employees [Member] | Restricted stock awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 13,950		$ 103,950
2014 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Incentive Plan, shares authorized	500,000						500,000
Expiration term	10 years
Outstanding stock options							436,748
2009 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Incentive Plan, shares authorized							869,565					652,174	217,391
Expiration term							10 years
Outstanding stock options							581,842	633,482
2009 and 2014 Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding stock options							1,018,590
Granted							1,416,091
Forfeited							115,398
Common shares available for grant							68,872

Stockholders' Equity (Deficit56

Stockholders' Equity (Deficit) (Schedule of Stock-based Compensation) (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation			$ 1,046,086	$ 722,358	$ 1,066,443	$ 571,924
Outstanding stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation	$ 245,289	$ 224,586	$ 942,136	$ 722,358	570,760	131,178
Non-employee stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation					$ 495,683	415,212
Restricted stock awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation						$ 25,534

Stockholders' Equity (Deficit57

Stockholders' Equity (Deficit) (Schedule of Stock Option Valuation Assumptions) (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%	0.00%
Expected volatility	83.62%
Risk-free interest rate	1.63%
Expected lives (years)	6 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility		107.00%	90.00%
Risk-free interest rate		2.06%	1.39%
Expected lives (years)		5 years 10 months 24 days	5 years 9 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility		110.00%	112.00%
Risk-free interest rate		2.23%	2.26%
Expected lives (years)		6 years 6 months	6 years 6 months

Stockholders' Equity (Deficit58

Stockholders' Equity (Deficit) (Schedule of Stock Option Activity) (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Shares
Outstanding, beginning balance	1,018,590	633,482	590,047
Granted	277,875	507,879	186,736
Exercised	(10,272)	(78,664)	(80,706)
Forfeited	(179,298)	(44,107)	(62,595)
Outstanding, ending balance	1,106,895	1,018,590	633,482
Weighted Average Exercise Price
Outstanding, beginning balance	$ 5.04	$ 3.36	$ 0.71
Granted	6.09	6.30	10.07
Exercised	1.97	0.60	0.67
Forfeited	6.50	3.19	1.96
Outstanding, ending balance	5.10	$ 5.04	3.36
Fair value of stock options vested		$ 1,704,121
Weighted average grant-date fair value	$ 3.33	$ 5.66	$ 8.51
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	7 years 4 months 24 days
Options Vested, shares	649,421
Options Vested, Weighted Average Remaining Contractual Life	6 years 2 months 12 days
Options Vested, Weighted Average Exercise Price	$ 3.89
unrecognized stock-based compensation expense, recognition period	15 months 24 days	14 months 27 days
Unrecognized stock-based compensation expense	$ 3,114,452	$ 3,872,221

Stockholders' Equity (Deficit59

Stockholders' Equity (Deficit) (Summary of Outstandng Stock Options) (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Options Outstanding
Balance		1,018,590
Weighted average remaining contractual life		7 years 9 months 22 days
Weighted Average Exercise Price		$ 5.04
Options Exercisable
Balance	649,421	473,696
Weighted average remaining contractual life	6 years 2 months 12 days	5 years 11 months 26 days
Weighted average exercise price	$ 3.89	$ 2.67
Options Vested or Expected to Vest
Balance		473,696
Weighted average remaining contractual life		5 years 11 months 26 days
Weighted average exercise price		$ 2.67

Income Tax (Schedule of Income

Income Tax (Schedule of Income Tax Expense (Benefit)) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Current expense:
Federal
State
Deferred expense (benefit):
Federal
State
Total

Income Tax (Schedule of Incom61

Income Tax (Schedule of Income Tax Rate Differences) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax [Abstract]
Federal income tax expense at statutory rate	$ (4,162,691)	$ (2,247,353)
State and local income taxes, net of federal benefit	(344,247)	(186,475)
Non-deductible expenses	239,213	4,985
Prior-period true-up	(161,018)	162,061
Research & development credit	$ (454,031)	(180,687)
Change in tax rate		$ 32,774
Stock based compensation	$ 135,008
Increase in valuation allowance	$ 4,747,766	$ 2,414,695
Total

Income Tax (Schedule of Deferre

Income Tax (Schedule of Deferred Tax Assets) (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Net operating loss carryforward	$ 8,141,857	$ 4,167,785
Research & development credit	961,445	424,739
Other	484,954	247,966
Valuation allowance	$ (9,588,256)	$ (4,840,490)
Deferred income taxes

Income Tax (Narrative) (Details

Income Tax (Narrative) (Details)	12 Months Ended
	Dec. 31, 2014USD ($)
Income Tax [Abstract]
Statutory federal tax rate	34.00%
Change in valuation allowance	$ 4,747,766
Operating Loss Carryforwards [Line Items]
U.S. net operating loss carryforwards	$ 42,039,675
Minimum [Member]
Operating Loss Carryforwards [Line Items]
U.S. net operating loss carryforwards expiration dates	Dec. 31, 2023

Related Party (Narrative) (Deta

Related Party (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2015
Related Party Transaction [Line Items]
Related party payable balance	$ 26,750	$ 13,000
Related party receivable balance	48,642	24,946	$ 58,017
Management [Member]
Related Party Transaction [Line Items]
Consulting fees	28,000	34,480
Board [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Officers' Compensation	32,000	5,000
Board [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Officers' Compensation	$ 37,000	$ 10,870

Net Loss Per Share (Reverse Sto

Net Loss Per Share (Reverse Stock Split) (Details)	1 Months Ended	12 Months Ended
	May. 31, 2013	Dec. 31, 2014
Net Loss Per Share [Abstract]
Reverse stock split, conversion ratio		0.4348
Reverse stock split	0.4348

Net Loss Per Share (Schedule of

Net Loss Per Share (Schedule of Reconciliation of Net Loss Applicable to Common Shareholders) (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Net Loss Per Share [Abstract]
Net loss	$ (5,427,709)	$ (3,127,269)	$ (14,357,325)	$ (8,508,592)	$ (12,243,211)	$ (6,609,864)
Net loss - non-controlling interest	(242,244)	(126,865)	(549,190)	(330,675)	$ (454,394)	(198,516)
Beneficial conversion charge						(2,300,000)
Preferred stock dividend						(361,668)
Net loss attributable to Heat Biologics, Inc.	$ (5,185,465)	$ (3,000,404)	$ (13,808,135)	$ (8,177,917)	$ (11,788,817)	$ (9,073,016)
Weighted-average number of common shares used in net loss per share attributable to common stockholders - basic and diluted	8,408,376	6,469,272	7,880,637	6,445,129	6,454,866	3,747,357
Net loss per share attributable to Heat Biologics, Inc.-basic and diluted	$ (0.62)	$ (0.46)	$ (1.75)	$ (1.27)	$ (1.83)	$ (2.42)

Net Loss Per Share (Schedule 67

Net Loss Per Share (Schedule of Antidilutive Securities) (Details) - shares	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Outstanding stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	1,106,895	836,961	1,018,590	633,482
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	17,392	17,392	142,392	178,159
Underwriters warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	125,000	125,000

Commitments and Contingencies68

Commitments and Contingencies (Narrative) (Details) - USD ($)	Jan. 24, 2014	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Commitments and Contingencies [Abstract]
Lease term	5 years
Monthly lease rent	$ 10,341	$ 11,638		$ 4,046
Rent expense			$ 100,973	$ 48,377

Commitments and Contingencies69

Commitments and Contingencies (Future Minimum Payments for Operating Lease Obligations) (Details)	Dec. 31, 2014USD ($)
Approximate future minimum payments for its operating lease obligations that have initial remaining non-cancellable terms in excess of one year
2,015	$ 192,833
2,016	218,271
2,017	224,282
2,018	231,010
2,019	194,401
Total	$ 1,060,797

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Mar. 15, 2015	Mar. 10, 2015	Mar. 09, 2015	Sep. 30, 2013	Aug. 31, 2013	Jul. 31, 2013	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Subsequent Event [Line Items]
Shares of common stock issued		1,640,000		100,000	100,000	2,500,000
Net proceeds from offering, , after deducting underwriting discounts, commissions, and other third party offering expenses		$ 11,100,000					$ 11,400,870			$ 540
Over-allotments [Member]
Subsequent Event [Line Items]
Shares of common stock issued		246,000
Subsequent Event [Member] | Severance agreement with Matthew Czajkowski [Member] | Vesting prior to the date of resignation [Member]
Subsequent Event [Line Items]
Exercise period	10 years
Subsequent Event [Member] | Severance agreement with Matthew Czajkowski [Member] | Vesting after the date of resignation [Member]
Subsequent Event [Line Items]
Exercise period	90 days
Subsequent Event [Member] | Consulting agreement with Danforth Advisors, LLC [Member]
Subsequent Event [Line Items]
Written notice period required to terminate agreement by the Company			30 days
Subsequent Event [Member] | Underwriting Agreement with Aegis Capital Corp. [Member]
Subsequent Event [Line Items]
Shares of common stock issued		1,640,000
Offering price (in dollars per share)		$ 6.50
Net proceeds from offering, , after deducting underwriting discounts, commissions, and other third party offering expenses		$ 11,100,000
Subsequent Event [Member] | Underwriting Agreement with Aegis Capital Corp. [Member] | Over-allotments [Member]
Subsequent Event [Line Items]
Shares of common stock issued		246,000

Fair Value of Financial Instr71

Fair Value of Financial Instruments (Schedule of Change in Fair Value of the Level III Stock Warrants Liability) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of stock warrant liability, beginning	$ 122,590	$ 92,150
Change in fair value during the period	7,263	30,440
Cashless exercises during the period	$ 323,021
Fair value of stock warrant liability, ending		$ 122,590

Fair Value of Financial Instr72

Fair Value of Financial Instruments (Schedule of Major Categories of Assets and Liabilities Measured at Fair Value on Recurring Basis) (Details) - Fair Value, Measurements, Recurring [Member]	Dec. 31, 2013USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock warrants liability	$ (122,590)
Total Liabilities measured at fair value	$ (122,590)
Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock warrants liability
Total Liabilities measured at fair value
Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock warrants liability
Total Liabilities measured at fair value
Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock warrants liability	$ (122,590)
Total Liabilities measured at fair value	$ (122,590)

Financing (Details)

Financing (Details) - USD ($)	Mar. 10, 2015	Sep. 30, 2013	Aug. 31, 2013	Jul. 31, 2013	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Common stock issued	1,640,000	100,000	100,000	2,500,000
Offering price	$ 6.50	$ 10	$ 10	$ 10
Net proceeds from offering, , after deducting underwriting discounts, commissions, and other third party offering expenses	$ 11,100,000				$ 11,400,870			$ 540
Over-allotments [Member]
Common stock issued	246,000